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Abstract
Coagulation testing is an important diagnostic tool for the detection of excessive bleeding risk or
obstructive clot formation (thrombosis), using blood samples from patients. Microfluidic flow devices
have been well established to provide insights on the impacts of shear rate, drug action, and disease state
on coagulation and platelet biology. The bulk of the microfluidic devices and assays used in the past have
relied upon manual assembly using poly(dimethylsiloxane) (PDMS), a material and construction method
not well suited to use in a clinical setting. This thesis describes the design and testing of a single-use,
storage stable evolution of previous PDMS microfluidic designs, manufactured via injection molding and
pressure-sensitive adhesive bonding. Using this device, we demonstrate the ability to make internally
consistent and repeatable measurements of platelet and fibrin fluorescence intensity in clots forming
under venous shear rate, using a bench-top LED microscope, and physiologically representative constantpressure driven flow. We also demonstrate the ability to detect a strong, dose-dependent reduction in the
fibrin fluorescence intensity signal in response to in vitro spiking of direct oral anticoagulants (DOACs).
Further, we showed the ability to reverse this inhibition, through the addition of small quantities of drug
reversal agents. In a separate study, the presence of DOACs in the blood of patients on the medications
was clearly detected. Utilizing the previously obtained data from in vitro spiking, the relative response of
DOAC patient blood with and without reversal agent was used to generate a quantitative prediction for the
current concentration of drug in their system. The field of coagulation testing has lacked a definitive
candidate for a fast, reliable means of accurately assessing patient anticoagulation status. Taken
together, the ability to both identify the presence and predict the quantity of DOAC in a patient’s blood
using a single-use microfluidic chip approach, as described in this thesis, represents a potential promising
new direction for coagulation testing at the bed-side.
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ABSTRACT
A SCALABLE, POINT-OF-CARE, MICROFLUIDIC APPROACH
FOR ASSESSING THROMBOSIS AND HEMOSTASIS
Jason M. Rossi
Scott L. Diamond

Coagulation testing is an important diagnostic tool for the detection of excessive
bleeding risk or obstructive clot formation (thrombosis), using blood samples from
patients. Microfluidic flow devices have been well established to provide insights on the
impacts of shear rate, drug action, and disease state on coagulation and platelet biology.
The bulk of the microfluidic devices and assays used in the past have relied upon
manual assembly using poly(dimethylsiloxane) (PDMS), a material and construction
method not well suited to use in a clinical setting. This thesis describes the design and
testing of a single-use, storage stable evolution of previous PDMS microfluidic designs,
manufactured via injection molding and pressure-sensitive adhesive bonding. Using this
device, we demonstrate the ability to make internally consistent and repeatable
measurements of platelet and fibrin fluorescence intensity in clots forming under venous
shear rate, using a bench-top LED microscope, and physiologically representative
constant-pressure driven flow. We also demonstrate the ability to detect a strong, dosedependent reduction in the fibrin fluorescence intensity signal in response to in vitro
spiking of direct oral anticoagulants (DOACs). Further, we showed the ability to reverse
this inhibition, through the addition of small quantities of drug reversal agents. In a
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separate study, the presence of DOACs in the blood of patients on the medications was
clearly detected. Utilizing the previously obtained data from in vitro spiking, the relative
response of DOAC patient blood with and without reversal agent was used to generate a
quantitative prediction for the current concentration of drug in their system. The field of
coagulation testing has lacked a definitive candidate for a fast, reliable means of
accurately assessing patient anticoagulation status. Taken together, the ability to both
identify the presence and predict the quantity of DOAC in a patient’s blood using a
single-use microfluidic chip approach, as described in this thesis, represents a potential
promising new direction for coagulation testing at the bed-side.
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CHAPTER 1 : INTRODUCTION
1.1 Hemostasis
1.1.1. Platelets
Platelets are anuclear, discoid cell fragments found in blood which have multiple
functions contributing to the process of hemostasis – the arresting of blood leakage from
damaged vasculature. Platelets, 2-4 microns in diameter, are formed from
megakaryocytes in the bone marrow via thrombopoesis and remain in circulation for
approximately 7-10 days after their formation [1]. When stimulated with any of several
agonists, platelets can transform into an activated state which promotes their adhesion
to both one another and to exposed subendothial tissue; a process that is also marked
by shape change and granule release [2]. To form a clot in vivo, platelets must
aggregate under flow in response to an injury. To achieve this, platelets first adhere to
the exposed collagen and von Willebrand factor (vWf) which are revealed by damage to
the endothelial cells lining a vessel wall. Collagen binding occurs via the GPVI receptor
and α2β1 integrin complex, and vWf engagement happens through the GPIb-V-IX
receptor, although this interaction is considered more important at arterial shear rates
[3]. Activation of platelets via collagen binding is significant; fibrillar collagens are
considered to be among the most potent platelet activating substances [1]. After this
primary aggregation phase, subsequent secondary aggregation occurs via positive
feedback release of ADP and TxA2 from activated platelets. Activated platelets bind one
another through bridging of fibrinogen molecules between the GPIIb/IIIa integrin complex
on separate platelets [1].
In addition to aggregating to form a hemostatic plug in their own right, platelets
also serve to support a series of enzymatic reactions known as the coagulation cascade.
1

Through the activation process, platelet membranes become charged and phospholipids
from the inner leaflet are exposed, which can act as a scaffold on which the coagulation
reactions can occur [4]. Thrombin, a reactive product of the coagulation cascade, can
also act as a platelet agonist and further activate platelets via interaction with protease
activated receptors PAR1 and PAR4 on platelet surfaces [1].

1.1.2. Coagulation Cascade
Apart from the action of platelets, the physiological process of coagulation is a
series of enzymatic reactions culminating in the formation of polymerized fibrin which
can form a mesh network to help stabilize clots. Upon initial vessel damage during an
injury, Tissue Factor (TF), is exposed along with the collagen in the subendothelium.
Tissue factor subsequently complexes with Factor VIIa from the circulating plasma to
form the TF:VIIa complex, also known as extrinsic tenase [5,6]. This complex is the root
of what is typically referred to as the extrinsic pathway, which ultimately activates Factor
X to Xa ( Figure 1.1). This is generally referred to as the initiation phase of coagulation.
The extrinsic pathway is considered to be the primary pathway by which factor Xa is
generated in vivo, but a second pathway also exists, known as the intrinsic pathway.
Intrinsic pathway activation is initiated by plasma interaction with negatively charged
surfaces, and the subsequent activation of factor XII to XIIa. The intrinsic pathway then
proceeds through the reactions of factors XI, IX, and VIII, and culminates in the
formation of the VIIIa:IXa complex, or intrinsic tenase. Whether Xa is generated via the
intrinsic or extrinsic pathway, it will subsequently complex with activated Factor V to form
Xa:Va, also know as the prothrombinase complex. This complex and the subsequent
reactions leading to Factor IIa (thrombin) and fibrin are referred to as the common
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pathway. Although initiation through the intrinsic pathway is considered less relevant in
vivo, parts of the pathway become important even when coagulation is initiated by TF,
as thrombin can activate Factor, V to Va, VIII to VIIIa and XI to XIa, enabling formation
of intrinsic tenase in the absence of factor XIIa [7]. This is referred to as the amplification
phase of coagulation.

Figure 1.1: The primary reactions of the coagulation cascade
The main reactions of both the intrinsic and extrinsic coagulation pathways, and the shared
common pathway [6].

One of the most significant results of the common pathway of coagulation is the
formation of large amounts of fibrin polymer from the plasma protein fibrinogen. This
3

polymerized fibrin forms a porous network and a loose clot structure which is highly
elastic and deformable [8]. Bleeding disorders resulting from deficiencies in coagulation
factors such as hemophilia A and B, and reduced life expectancy in fibrinogen knockout
mice indicate that fibrin is necessary for maintenance of hemostasis [8] . The phase in
which the significant amounts of thrombin formed in the amplification phase have
precipitated the formation of physiologically relevant amounts of fibrin is known as the
propagation phase [6].

1.1.3. Thrombosis
While the processes of platelet aggregation and thrombin formation through the
coagulation cascade are important physiological responses to tissue damage, excessive
or unneeded clotting can cause extreme deleterious effects. Contemporaneous with
platelet and coagulation activating processes, down-regulating mechanisms are
continuously at work in blood to prevent excessive accumulation of activated platelets
and thrombin. Antithrombin, heparin cofactor II and activated Protein C help to inhibit
thrombin and its reactivity, while prostaglandins released from the endothelium can
stimulate inhibitory internal signaling pathways in platelets [9,10]. In addition, fibrinolytic
processes begin through the activation of plasminogen to plasmin upon contact with
tissue plasminogen activator and work to dissolve and break apart fibrin clots [9]. When
either these down-regulating mechanisms become underactive, or the procoagulant
mechanisms become overactive, excessive clotting can occur causing occlusive thrombi
to form which can stop blood flow in vessels. Both venous thromboembolism (VTE),
caused by thrombus formation in the veins and subsequent embolization posing risk of
pulmonary embolism, and Myocardial Infarction (heart attack) are potential life
4

threatening thrombotic complications which can result from disregulated hemostatic
pathways.

1.2 Standard Laboratory Coagulation Testing Methods
1.2.1. Prothrombin Time
The prothrombin time (PT) is a blood plasma assay used to measure the time
required for fibrin to be generated after the activation of the coagulation cascade by
addition of TF – typically referred to as clot time [11]. Since coagulation in this assay is
initiated by TF, as shown in Figure 1.1, this is considered an extrinsic pathway
dependent test. PT is run using plasma anticoagulated with sodium citrate, which
chelates and sequesters calcium ions which are required for platelet activation and most
of the coagulation reactions to proceed. Typically, TF is added in these tests as
thromboplastinin – a mixture of TF protein and phospholipid material which can act as a
scaffold for the coagulation reactions in the absence of activated platelets (Figure 1.2).
This thromboplastin is generally added in a calcium containing buffer in order to restore
the plasma’s ability to coagulate by replacing the chelated calcium ions. The endpoint of
the assay is indicated by the formation of fibrin as detected either optically or
mechanically, and typically occurs 10-15 seconds after initiation [11]. PT data is
sometimes presented as an internationally normalized ratio (INR) defined as the ratio of
patient’s clot time to a reference clot time which has been defined as “normal”, raised to
the power of the international sensitivity index (ISI) (Equation 1.1) [12]. This approach
enables comparison of PT values gathered across different equipment and calibrations.

5

Figure 1.2: Platelet interaction with coagulation.
Platelets can potentially be sources of tissue factor, bind and store Factor V from plasma as
factor Va, and offer a scallfold for extrinsic and intrinsic tenase and prothrombinase [5].

Eqn. 1.1

(

PT patient
INR=
PT normal

)

ISI

Despite clot times being relatively short for PT/INR, the full cycle time of the test
can be more than 60 minutes [13]. Further, since the INR was originally developed for
patients on Vitamin K antagonists and includes data from such patients in the calculation
of the ISI, the application of the approach to patients not on oral anticoagulants is not
necessarily rigorous [13]. The test also cannot differentiate the independent
contributions to coagulation, and provides no information on platelets or clot stability.

1.2.2. Activated Partial Thromboplastin Time
Activated partial thromboplastin time (aPTT) is another plasma assay that
measures the time to fibrin formation like PT, but initiates coagulation via the intrinsic
6

pathway – through activation of factor XII – rather than the extrinsic pathway (Figure
1.1). Like PT, the assay is run using citrated plasma, and calcium ions and phospholipid
are added to the sample prior to initiation. Typically, a charged inorganic material such
as kaolin or silica is added to initiate activation of factor XII. Clot times are longer for
aPTT than PT, at around 25-35 seconds [11]. Activated partial thromboplastin time
shares many of the major limitations of prothrombin time, most notably the excessively
long turnaround time [13]. In addition, both tests are performed in the absence of
platelets and red blood cells, limiting the biology they are able to interrogate. Inhibitors
present in physiological coagulation such as protein C are also not necessary
represented completely in either of the assays due to the lack of thrombomodulin,
meaning inferences about the total amount of thrombin being generated in these assays
can be misleading.

1.2.3. Viscoelastic Measurements
Viscoelastic measurement of clots has been in use at the lab scale since the late
1940’s and relies on the detection of changes in the rheology of blood from more viscous
to more elastic as clotting occurs and fibrin forms [14]. The main outputs of this
measurement are the timing of the transition from primarily viscous to elastic, and the
stiffness of the clot once that transition occurs, as defined by the shear elastic modulus
[10]. The most common implementation of this approach is the TEG-5000s device,
wherein the deflection of a torsion wire in response to increased clot elasticity is
monitored as a temperature controlled cup containing whole blood is oscillated [14]. The
use of whole blood, unlike PT/INR or aPTT means that platelet influence in the clotting
process can be captured by thrombelastography (TEG).
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Experimental approach used for the TEG 5000 instrument. About 0.4 mL of blood is added to the
cup and rotates in an oscillatory manner to create rotational force on the pin. The pin’s deflection
is then measure electromagnetically [14].
Figure 1.3: Schematic of Viscoelastic Measurement

The deflection of the pin in Figure 1.3 can be detected by an electromechanical
proximity sensor plot amplitude versus time, yielding a characteristic curve as shown in
Figure 1.4. Initially, prior to significant thrombin/fibrin formation or platelet aggregation,
there is minimal deflection and the amplitude remains constant. The onset significant of
deflection is marked by an ‘R’ parameter which is functionally similar to the clot time from
the plasma assays, ranges normally from 4-8 minutes. Other typically used parameters
include the maximal deflection denoted as the maximum amplitude (MA) and the slope
of the amplitude with time at the midpoint between onset and the MA (α), which captures
rate of clot formation. Unlike the previously described plasma assays, TEG can produce
data on the stability of clots by maintaining the experiment through the onset of clot lysis
mediated by plasmin, and the restoration of viscous behavior. TEG data is impacted by
the processes of coagulation and platelet aggregation, although the contributions of
8

each cannot be completely decoupled. The specific values of R and α generally reflect
the rate of coagulation, while the time of maximum amplitude is generally more reflective
of platelet activation status and quantity [14].

Figure 1.4: TEG example output data
Example results for TEG experiment based on pin deflection as described in Figure 1.3. Reaction
time (R), α angle and maximum amplitude are the main values derived from these plots [14].

Rotational thromboelastography (ROTEM) is a largely similar approach to the
TEG system, with the primary difference being the way in which the cup and pin and
move about one another. In the ROTEM system, the cup is held stationary, while in TEG
the pin is held stationary and the cup is rotated. First generation devices for both
technologies were marked by significant variance from lab to lab and instrument to
instrument [14]. Although neither of the viscoelastometry methods has been considered
an international standard in coagulation testing like the PT/INR and aPTT tests, the
technology has been in use for several decades now, for research purposes in
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indications such as trauma and anticoagulation therapy detection. Still, the reliability and
accuracy of results generated by these methods is still somewhat controversial, and their
adoption has not been universal [15,16].

1.3 Microfluidic Platelet and Coagulation Testing methods
1.3.1. Flow Hemodynamics and Coagulation
One common deficiency in each of the previously described laboratory tests is
that none of them capture full physiological hemodynamics by including the impacts of
flow on the coagulation process. The specific properties of the flow field through a vessel
govern the convective mass transport that can occur for coagulation factors and other
reactive species into and out of the growing thrombus. In addition, the flow regime can
impact both cell to cell interactions and cell interactions with the boundaries of the
particular flow path, either the physiological vessel walls or the walls of a flow chamber
[17]. At very low shear rates, cell to cell interactions, particularly between red blood cells
can substantially modify the rheology of the fluid, owing to rouleaux formations that can
occur as the flat side of the erythrocytes adhere to one another [17]. In this way, blood
viscosity depends strongly on local shear rate, and therefore the particular
hemodynamics the environment being monitored, with lower shear rates yielding higher
viscosity [2]. On the opposite end, high shear rate environments have been
demonstrated to activate platelets and alter both the manner in which TF is distributed
throughout a clot and the rate of coagulation factor activation [17,18]. There has also
been evidence that TF originating in the blood is a major source of coagulation initiation
in vivo, and therefore the convective transport of this blood-borne tissue factor will also
be highly flow dependent [19]. Shear rate and flow directionality has also been well
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demonstrated to have a major impact on the endothelial cells lining vessel walls,
affecting both their morphology and alignment, and the relative amounts of receptors
expressed on their surfaces [20].
Initial experimental attempts at addressing the impact of flow phenomena on
coagulation in vitro primarily utilized large parallel plate flow chambers or glass capillary
devices. Flow chamber devices consist of parallel plates with variable spacing to achieve
different shear rates, and typically utilize some form of collagen fibril on one of the plate
surfaces to initiate platelet adhesion, and lipidated tissue factor to induce coagulation,
and have been largely successful in recapitulating the processes which regulate arterial
thrombosis [17,21]. A major drawback, however, is that these flow chambers require
large reservoirs of blood and lengths of tubing in order to pump blood quickly enough to
achieve the physiological shear rates of interest. Device gap dimensions are typically
100-200 microns and chambers can require up to 10 mL per assay. Miniaturized
perfusion chambers and glass capillary based devices were developed to help mitigate
this issue and have been used successfully as well for several studies relating to critical
concentrations of TF required for coagulation and leukocyte adhesion [21–23]. Still,
these smaller flow chamber and capillary devices remain relatively restrictive in terms of
the parallelization and geometric freedom which they allow.

1.3.2. PDMS Microfluidics
The application of photolithography and soft lithography techniques to platelet
and coagulation assays has enabled the development of poly(dimethylsiloxane) (PDMS)
devices which largely address the limitations of the previous technologies. Micron scale
resolution and freedom in the relative placement of independent flow channels in
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proximity to one another enable high degrees of parallelization and repetition of
experimental conditions, while utilizing very small volumes of blood (<0.5 mL per
experiment). Flow paths in devices manufactured by PDMS soft lithography typically
have rectangular channel geometries in the 10-500 micron range, yielding a laminar
velocity profile of the form:

y
)
1
h
z
]sin( n π )
∑ n3 [1−
w
h
n=1,3,5. ..
cosh( n π
)
48 Q
2h
u( y , z)= 3 ×
∞
192 h
w
π hw
1− ∑
tanh( n π
)
5 5
2h
n =1,3,5. .. n π w
cosh( n π

∞

Eqn 1.2

for -w/2<y<w/2 and z<=h. With rectangular channels of high enough aspect ratio (w/h),
this flow profile provides an approximation of two-dimensional infinite parallel plate flow
within the middle portion of the channel, away from the side walls. Rectangular geometry
is both a necessity of the manufacturing method, and an aid in visualization; since the
platelet accumulation and coagulation reactions are localized on a plane perpendicular
to the field of view of an epifluorescence microscope, the entire clot can be image
simultaneously.
The development of multiplexed PDMS devices for running multiple experimental
conditions on a single chip has enabled studies on the effects of drugs, disease states,
and thrombogenic surfaces [24–28]. The ability to customize the hemodynamic
conditions has also allowed for specific device and study design for high shear vWf
capture and transthrombus transport and pressure gradients [29–32]. The majority of
PDMS device studies have utilized optical detection via immunofluorescence to
transduce signal from the clot data, but other approaches including electrical impedance
and mechanical responses have been used as well [33,34]. Similar microfluidic devices
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can also be manufactured in poly(methyl methyacrylate) (PMMA), cyclic-olefincopolymer (COC) and other materials by alternative manufacturing techniques such as
laser micromachining, injection molding, and lamination techniques [35]. Despite the
scope of materials and geometries available, and although microfluidic devices have
been used to study blood from patients from clinical visits, no single chip technology has
presented itself as a replacement for the gold standard coagulation and platelet function
tests available. A device which utilizes the unique advantages of microfluidic technology,
but which has been adapted to be storage-stable and operable by untrained personal
therefore represents an opportunity to offer unique advantages in hemostasis testing.

1.4 Point-of-Care Testing Methods
1.4.1. Unmet needs in Coagulation Testing
Although routine coagulation testing by the standard laboratory methods
described earlier can provide valuable insight to physicians, an emerging need for faster,
easier to use approaches has presented itself over the last decade. Direct oral
anticoagulants (DOACs) have, during this period, increased rapidly in usage for
indications such as atrial fibrillation (a-fib) and deep vein thrombosis (DVT), owing to
their increased safety due to reduced risk adverse events such as intracranial
hemorrhage, and their lack of need for routine blood tests to monitor drug levels as
required by previously used anticoagulants such as warfarin [36]. As a result of this,
more than 4 million patients were currently on DOAC therapy as of 2016 [37]. Although
DOACs have shown increased safety, as with any anticoagulant, they carry with them an
increased risk of adverse bleeding events, particularly in vulnerable populations such as
the elderly and those on certain other medications [38]. In addition, patients who
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experience traumatic injury or who must undergo urgent intervention surgery
(perioperative management) while on DOAC therapy are similarly at-risk, and the ability
to detect their current anti-coagulation status has presented itself as a more and more
pressing need. Tests such PT and aPTT have been shown to yield variable responses to
DOAC drugs depending on the reagents used, with their use being largely limited to
screening assays, and no standarized test to detect and quantify DOACs has emerged
in their place [38]. Although drug reversal strategies have been developed to reduce
bleeding risk for patients on DOACs in specific scenarios, their prohibitively high cost
( up to $50000/dose) means that methods for detection of DOAC levels in both a cost
and time efficient manner to assess the need for those reversal agents is critically
important.
Similarly, the need to assess bleeding risk in proximity to surgical procedures
regardless of the presence or absence of anti-coagulation therapy is an emerging unmet
need. Cardiac surgery has been associated with a high risk of coagulopathic bleeding,
with as many as 20% of patients undergoing procedures experiencing significant
bleeding events [39]. In cases such as these, the timing associated with obtaining the
results is critically important, and so increasingly point of care (POC) coagulation and
platelet assays have been utilized to inform decision making in acute situations. The
ability to detect specific coagulation disorders in short time periods, then, is a major
cause of the rapid increase in number and type of point of care diagnostic methods.
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1.4.2. Current Point-of-Care Technologies
1.4.2.1

Platelet function Assays

Many of the POC testing methods currently available focus on either platelet function or
coagulation function exclusively. The VerifyNow (Accumetrics) is one such assay
focusing on detection of platelet response to specific drugs. The assay detects changes
in turbidity optically upon activation of platelets in proximity to fibrinogen coated beads,
with either adenosine diphosphate (ADP) or arachadonic acid (AA). As platelets are
activated, Gp(IIb)/IIIa binds to the fibrinogen on the beads, forming bridges, causing
aggregation and changes in light transmittance [40]. There are specific editions of the
assay for P2Y12 inhibitors (such as clopidogrel) and for Aspirin, but in either case the
assay requires ~2 mL of blood and has provides results in <20 minutes [41,42]. The
assay is widely used for undergoing coronary interventions and has been FDA approved
for platelet function testing, but is considered quite expensive.
The platelet function analyzer (PFA-100/200) (Siemens) is a similar platelet
focused assay. Unlike the VerifyNow, the PFA utilizes an open system flow assay where
whole blood is delivered via vacuum pressure across a collagen membrane coated with
an additional variable agonist such as ADP. As platelets are activated, they accumulate
in the membrane and eventually cease the flow – yielding a ‘clot time’ as a result [40].
The assay is simple and uses less than 1 mL of blood, but can be highly dependent on
the vWf level in a particular sample, and on the erythrocyte concentration as well [42].
Both TEG (Haemonetics) and ROTEM (Pentapharm) have iterations of their
viscoelastic assays designed specifically for the detection of platelet aggregation via
specific activation via ADP, and which can be used in bedside operation as a POC
diagnostic [42]. In addition, the TEG-6s is newer iteration of thrombelastography
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technology utilizing microfluidic cartridges to handle small volumes of blood and oscillate
the fluid via a resonance method rather than cup and pin motion [43]. The TEG-6s can
be used to provide information on platelet-fibrin clot formation by utilizing specific
agonists as with the previous versions of the technology [42]. Although the TEG-6s
reduces the volume of blood required and the complexity of the experiment, the assay
still requires 45 minutes for full results and has been shown to have limited correlation
with patient outcomes in clinical settings [43].

1.4.2.2

Coagulation function assays

Just as some POC assays have focused on platelet function detection, others
have focused on detection of thrombin and fibrin formation and the coagulation cascade.
POC iterations of the previously described PT/INR and aPTT are increasingly becoming
available. The Coumatrak (Biotrack) assay has been available for use in bedside
operation since the 1990’s and uses of a battery-powered laser photometer to measure
the clot time previously described. Whole blood is obtained from standard lancet fingerstick, and added to a cartridge containing thomboplastin [39]. The device shows
significant time and cost savings over lab based PT/INR but has issues with incomplete
correlation with laboratory results and concerns about the accuracy and precision of INR
values [44]. The Coaguchek system from Roche is a more recent miniaturized version of
the technology which similarly utilizes whole blood from finger-stick, but with an
electrochemical detection method and a much smaller form factor. Results from the
device have shown generally good correlation with laboratory INR analysis, but some
results have been shown to differ >15%, and in some cases would cause different
clinical decision making up to 33% of the time [45,46]. Similar devices have been
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released by CoaguSense and Abbott Laboratories, but all are generally subject to
incomplete agreement with laboratory PT/INR and the fundamental limitations of the
PT/INR assay.

1.4.2.3

Complete Hemostasis Assays

Several technologies exists which have the capability to detect both platelet
function and coagulation simultaneously. The T2 Magnetic Resonance assay is one
such technology which detects changes in the transverse relaxation time of nuclear
magnetic resonance as clotting proceeds upon the addition of stimuli. As water’s
molecular motion becomes more restricted as clotting proceeds, changes are caused in
their spin-spin relaxation times [47]. Applying algorithms to T2 relaxation curves allows
independent attribution of behavior to red blood cells, plasma proteins and platelets.
Experiments are run in cuvettes on a portable benchtop reader. The assay requires very
small volumes of blood (~.04 mL) and provides results in approximately 15 minutes, but
does not capture any contributions of flow to the hemostasis process [48].
As described earlier, viscoelastic methods such as TEG and ROTEM can be
utilized in POC operation and can be made to provide insight on platelet function as it
pertains to specific receptors such as P2Y12, through specific modifications of the assay
(ex. TEG PlateletMapping). In normal mode of operation, however, both TEG and
ROTEM generally capture the contributions of thrombin, fibrin formation and coagulation
to blood rheology far more significantly. In this way, the methods can provide full insight
on hemostasis, typically not within the same experiment. Still, the TEG-6s POC device
can generate the same parameters as and has shown good agreement with the cup and
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needle iterations such as the TEG5000, with no reagent handling and minimal fluid
handling [43].

Table 1: Selection of POC hemostasis assays
Detection

Sample

Platelet
Detection

Coagulation
Detection

Disadvantages

TEG-6s

Optical detection of Citrated Whole
Viscoelastic Changes blood

Yes (with
yes
modified assay)

Variable results,
relatively slow, No
flow

VerifyNow

Optical Detection of
bead aggregation

Whole blood

yes

no

Relatively
expensive, No
flow

PFA-100/200 Detection of Pressure Whole blood
Drop

yes

no

Wide normal
range

T2
Resonance

T2MR of water

Whole blood

yes

yes

Unintuitive output
data, No flow

Miniaturized
PT/INR

Variable

Whole blood

no

no

No platelet
contribution, No
flow

PDMS
Microfluidic
Approaches

Variable, typically
immunofluoresnce

Whole blood
(CTI)

yes

yes

Labor intensive,
not designed for
POC

1.4.2.4

DOAC Detection Assays

In addition to the general hemostasis and platelet function assays described
above, a subset of assays have been developed with the specific aim of detecting the
presence of DOACs in blood samples. ClotChip (Xatech) is a dielectric spectroscopy
assay that measures changes in the electrical permittivity (via impedance) of whole
blood in response to coagulation proceeding, and corresponding changes red blood cell
interfacial polarization, using a small volume microfluidic device [49]. For a fixed
frequency, the presence of thrombin (or factor Xa) inhibiting drugs shifts the timing of a
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characteristic peak in electrical permittivity to later timepoints, and in this way DOAC
presence can be detected. The chip has also been adapted to be read in a hand-held
reader facilitating application to POC settings. In clinical work with patients on DOAC
drugs, however, the AUC for receiver operating curve (ROC) analysis for the presence
of DOAC was found to be as low as 0.82 for apixaban, indicating a somewhat limited
detection sensitivity for certain DOACs [49]. Further, the general assay does not
capture the contributions of flow to hemostasis, and utilizes a somewhat unintuitive
metric in permittivity. Another DOAC specific POC assay that has been developed is a
microfluidic flourescence assay by CoaguloMed. Fluorescence intensity is monitored as
a sample of blood plasma labeled with fluorescent-conjugated fibrinogen undergoes
coagulation in a custom designed microfluidic device under quiescent conditions. As
fibrin polymer is formed, the optical signal changes until the process is complete and a
clot time is specified [50]. The optical detection of fluorescence signal is carried out in a
handheld reader device, making use in clinical application easy. In work with clinical
patients on DOACs, ROC analysis yielded and AUC of .984 for detection of the
presence of a DOAC, indicating reasonably good sensitivity for the drugs. In addition,
coagulation in the assay is initiated with 2 different agonists (A and B), one upstream of
Xa and one downstream of Xa, yielding the ability to differentiate between IIa and Xa
inhibitors. As with Xatech, however, the assay is carried out under static conditions, and
additionally can only be run with plasma, rather than whole blood. Perosphere Inc. have
also developed an assay for DOAC detection, utilizing infrared spectroscopy to detect
the formation of fibrin polymer in whole blood samples, which can be run on whole blood
with no anticoagulant [51]. Thus far, however, DOAC detection has only be
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demonstrated in rats. Table 2 shows a qualitative comparison of the difference DOAC
assays.

Table 2: DOAC specific POC assays
CoaguloMed

PeroSphere

XaTech

Flow

No

No

No

Detection Technology

Fluorescence Microscopy

IR Spectroscopy

Dielectric
Spectroscopy

Test Time

10 min

<5 min

15-30 min

Advanced Analytics/Data
Processing

Multivariate Regression Modeling
N/A

N/A

Calcium or No
additives

Calcium

Reagents Requirement

Fluorescent Labels, ‘Agonist A’,
‘Agonist B’, Calcium

Differentiation of Xa and
IIa inhibitors

w/ upstream and downstream
activators (agonist ‘A’ and ‘B’)

N/A

N/A

Blood product
compatibility

Whole blood or Plasma

Whole blood or
Plasma

Whole Blood

Platelet Diagnostic

No, no detection

No, No detection

Partial, inferential
detection

Anti-coagulant

Citrate

Citrate or None

Citrate

Form Factor

Handheld

Handheld

Handheld

Extensibility to new
analytes

Extensible, but no platelet
receptors

No

No

Clarity of metrics

FI scales with fibrin clot size, Clot
time is intuitive, Clot score is
highly manipulated

Clot time intuitive, IR
absorbance peak and
decay behavior
abstract.

Permittivity behavior
abstract. Platelet
behavior unintuitive.

Quantification or
Presence only

Presence

Presence

Presence
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CHAPTER 2 : ADAPTING PDMS MICROFLUIDIC DEVICES FOR
USE IN POINT OF CARE APPLICATIONS

2.1 Introduction
The monitoring of blood coagulation, anti-platelet therapy, anticoagulation
therapy, hemophilia therapy, surgical bleeding, trauma bleeding, and platelet function
form the basis of a very large (> $1 billion) diagnostics market. Few devices or systems
exist on the market for monitoring blood under flow conditions analogous to those that
exist within the human body and those that do have limited utility and only operate in the
absence of full coagulation that includes thrombin and fibrin generation. Microfluidic
assays based on PDMS soft lithography have offered solutions in each of these fields
while retaining physiological flow and full coagulation biology, but suffer from several
limitations which preclude their straightforward application clinical monitoring [25–27,52–
54].
Generally, microfluidic devices are designed for functionality and ease of
fabrication, rather than ease of use – e.g., inlet wells being arranged in a semicircular
fashion, rather than being aligned linearly for use with a multichannel pipette. Further,
these devices typically need to be passivated in some way to prevent off-target platelet
and coagulation activation, typically with bovine serum albumin (BSA). In some devices,
this process can be quite inefficient and require multiple steps: 1) inlet wells are filled
with buffer one at a time, 2) buffer is drawn through the device through the outlet, and 3)
excess buffer from each inlet wells is removed manually prior to blood addition – a
process which scales with the multiplexing of the experiment. In addition, fluid delivery
for these assays is often performed by either gravitational pressure head or withdrawal

21

through a syringe pre-filled with water using a syringe pump, with both methods requiring
significant set-up time and some training to execute correctly [26,32,55]. A final
consideration is that for many parallelization strategies in microfluidics, several distinct
inlet conditions are combined at the outlet after the area of detection for streamlined fluid
handling [26,32]. This allows the coagulation processes to occur semi-independently for
each experimental condition, without requiring dedicated fluid driving for each one. This
approach has inherent limitations, however, as there can be significant cross-talk from
one channel to another as clots approach occlusion and their fluidic resistance increase
sharply. Flow can then be diverted to certain experimental conditions (the least
occluded), changing the shear rate and altering the nature of the experiment. In this way,
if parallelization of channels can be achieved while avoiding this cross-talk, experiments
could be run longer and with complete independence of the experimental conditions.
The opportunity exists, therefore, for a microfluidic device specifically designed for use
by untrained personnel to provide unique insight on platelet function and coagulation
biology in clinical settings.

2.2 Materials and Methods
2.2.1. Device design and flow simulation
A previously published eight channel microfluidic device was used as a basis for
channel dimensions (250 μM x 60 μM) and focal imaging region design, while the
footprint was modified substantially [26]. Inlet wells were re-arranged to a linear
orientation with 96-well plate standardized spacing (9 mm) such that a multichannel
pipette can fill each one simultaneously. For the original, design the semi-circle
orientation was selected such that the length of channel between the wells and the focal

22

region, and therefore fluidic resistance, for each of the 8-channels was identical. This
allows uniform flow in each channel for fluid delivery mediated by a single pressure
source at the outlet, as verified by relative bead populations measured by flow cytometry
[26]. To recapitulate this uniform flow with the linearly arranged inlet wells, the
microfluidic resistance (Eqn. 2.1) was again held constant between the inlet well and the
converged focal regions, where the channels are oriented in parallel and have a spacing
of 125 μm.
Eqn. 2.1

R=

[

wh3 1−

12 μ L
∞

192
∑ (
π 5 w n=1,3,5. ..

]

nπ w
)
2h
)
n5

tanh (

In order to prevent variations in the platelet margination or red blood cell concentration
via Farhaeus effect, and avoid excessive shears that may activate platelets, the crosssection of each channel retained as close to constant as obtainable, such that wherever
possible, additional length was added for the interior channels via circuitous paths, and
altering of channel width was done sparingly.
Previously designed microfluidic devices have been structured with all inlet wells
converging to a single outlet well, for ease of fluid handling. With this arrangement,
however the channels of interest act as parallel flow paths, meaning that the flow rate in
one of the channels is affected by changes in resistance to the other channels, for a
fixed total flow rate as shown in Equation 2.2 where, R is the hydraulic resistance of a
channel and Q is volumetric flow rate [56]. To reduce the potential for fluidic cross-talk
between channels via changes in resistance as clots reach occlusion, the single outlet of
the previous design was replaced with individual outlets, each emptying into a single
collection reservoir open to atmosphere on the device’s surface. In addition, a PDMS
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manifold was built around each of the inlet wells, allowing positive pressure from a single
source to address each simultaneously.

Eqn. 2.2

1
Rn
Q n=
Q
1 1
1 total
+ ...
R1 R 2 R N

To address the need for more streamlined process for device passivization by
pre-filling with a protein solution (priming), an additional inlet port was added to the
device flow path, in fluidic communication with both the inlets and outlets. Also, for each
channel, a small region connecting the end of the converged focal region to the outlet
reservoir was added, with a smaller channel width than the rest of the device such that
the resistance (Eqn 2.1) for this small segment was equal to the resistance of the full
width (250 μM) up to this point. The flow path from the additional priming inlet splits and
branches to each channel at the point where the full width channel meets the condensed
width channel; in this way fluid injected through the priming inlet reaches the outlet
reservoir and in the inlet well at the same time without accumulating an excess of
priming fluid in either location. BSA (0.5% in HEPES-buffered saline pH=7.4) was used
as priming buffer for all experiments. Steady state flow simulations (COMSOL 5.3a)
were performed to verify uniformity of flow rates in each of the channels and to verify
wall shear rates in the focal region. Aqueous Food-grade dye was used for visualization
and confirmation of priming procedures.

2.2.2. Blood Collection and labeling
Whole blood was obtained from healthy individuals via venipuncture into direct
thrombin inhibitor PPACK to a final concentration of 100 μM. Informed consent was
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obtained for each volunteer and all procedures were performed in accordance with IRB
approval from the University of Pennsylvania’s Office of Regulatory Affairs and the
Declaration of Helsinki. Platelets were labeled with PE-conjugated mouse anti-human
CD61 (BD). For in vitro addition of acetylsalicylic acid (aspirin/ASA), crystalline solid was
dissolved in DMSO at 500 mMl, diluted in HBS, and then finally further diluted into blood
for final concentrations of 50 and 500 μM.

2.2.3. Device Fabrication and Imaging
Microfluidic devices were fabricated using poly(dimethylsiloxane) (Ellsworth
Adhesives) from silicon masters, made using KMPR (MicroChem Corp.) negative
photoresist, spincoated to 60 μm on 100 mm wafers (Pure Wafer). Inlet and outlet ports
were made using 0.5 mm ID biopsy punches. Additional PDMS retaining walls were
added to both the inlet region and out region to act as reservoirs, made by cutting a
rectangular hole within a slab of PDMS (Figure 2.1). For the inlet side, a single slab of
PDMS was then placed on top of the retaining walls with to make a pressure seal such
that a positive pressure regulator (Fluigent), hooked up to a diaphragm pump could
apply a single pressure to all inlet wells simultaneously by being inserted into a biopsy
punch through-hole through the slab (Figure 2.1). Pressure was calibrated such that an
initial flow rate of 1 μL/min (γ= 100 s-1) was obtained (7.5 mmHg). For the outlet side, the
reservoir was used to collected blood as exits from the outlets of each channel. A luerlock check valve (Qosina) was attached to the device at the priming inlet using a 23
gauge blunt needle with plastic hub. Channels were spaced 125 μm apart for the focal
region such that two at a time could fit within the field of view of 10x objective for an
inverted epifluorescence microscope (IX81, Olympus). Type-1 equine fibrillar collagen
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(Chronolog) was applied in a 250 μm strip using a single channle PDMS patterning
device on a glass slide treated with SigmaCote (Sigma Aldrich). Channels were pre-filled
prior to experiments with a 0.5 w% BSA in HBS solution in order to passivate all
surfaces.

Pressure
Controller

A

B

Pressure Seal
Spacer
Sample Wells
Channel

Figure 2.1: Pressure control and fluid perfusion in 8 by 1 PDMS device
Top View (A) and Side View (B) of fully assembled PDMS device. A sealed air head above the
wells is pressurized using a diaphragm pump and Fluigent pressure controller, connected to the
device with a 23 gauge needle slotted into a biopsy punched thru-hole in the PDMS slab.

2.3 Results
2.3.1. Device Design and Validation
A re-oriented 8-channel PDMS device was successfully designed with inlet wells
arranged linearly with the spacing of a 96 well plate (9 mm) (Figure 2.2). Some
reductions in channel width were necessary in order to keep the entire footprint of the
device as small as possible; the specific dimensions used for each channel segment are
shown in Figure 2.2B, where only four channels are displayed due to device symmetry.
A dedicated priming port was added such that priming fluid can be injected through a
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check valve to fill the device with BSA solution, where the priming fluid conduit thereafter
behaves a ‘dead end’ for the experiment (Figure 2.3) Flow rate uniformity was verified
by COMSOL steady-state 2D laminar flow simulations, yielding equivalent velocity
profiles in each of the 8 channels for a fixed pressure at each inlet of 15 mmHg,
confirming that the fluidic resistance in each channel was identical (Figure 2.4).

A

B
Outlet Collection Reservoir

Check Valve

Back-Prime Flow Path
Forward Flow Path

Wells with PDMS manifold

Pressure Source

80 µm
165 μm
180 μm
197 μm
202 μm
205 μm
207 μm
211 μm
222 μm
230 µm
233 µm
250 µm

Figure 2.2: 8 by 1 PDMS device channel schematic
Flow path scheme and back prime approach (A), Fluid is injected into the devices through the
back-priming port which fills the channels both to the inlet and outlet (red). Blood is added to the
inlet wells and displaces the priming solution to the outlet, but not towards the check valve. (B)
Dimensions of the each channel (channels are symmetric about center line), where fluidic
resistance was kept constant to keep flow rates and shear rates constant over the reaction zone
identical.
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A Empty

B Primed

Priming Fluid

Figure 2.3: 8 by 1 PDMS device priming
Visualization of priming process. An empty device (A) is filled with priming fluid (blue food
coloring) through the priming port with check valve using luer lock plastic syringe. The filled
device has fluid advance up to the inlets and outlets simultaneously to prevent waste (B).

Figure 2.4: COMSOL Simulation for velocity in 8 by 1 PDMS device
Steady state laminar flow COMSOL simulation results for velocity profile, given 15 mmHg
pressure at all inlets and 0 mmHg pressure at all outlets. Uniform coloring for each channel
indicates equivalent flow and equivalent shear rates, suggesting hemodynamic conditions for
each channel are identical. Check valve was modeled as a no-transport wall condition.
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2.3.2. Whole Blood Experiments
As a proof of concept, clotting behavior of healthy donor blood was verified for
venous shear rates. Perfusion was driven through all n = 8 channels simultaneously by
application of positive pressure (7.5 mmHg) at the inlet wells. Uniform behavior was
observed over all 8 channels, with channel occlusion occurring at approximately 600
seconds in each Figure 2.5. No obvious differences in clot morphology were observed
compared to clots formed under flow driven by fluid withdrawal via syringe pump.
Consistent morphology across this chip suggested to major differences in shear rate in
each channel.

Figure 2.5: Whole blood clotting using in-line PDMS device
Montage of fluorescence images for PE-anti-human CD61 stained platelets, where three time
points are shown for each channel for N=1 donor (A). Average fluorescence intensity across
device versus time (B), shows characteristic behavior for PPACK anticoagulated blood.

To investigate the ability of the newly designed device to detect drug action, two
different concentrations of aspirin were evaluated; 50 and 500 μM. A dose-dependent
reduction in platelet fluorescence intensity was observed for an initial wall shear rate of
100 s-1 7.5 mmHg Figure 2.6. This suggests the after primary aggregation via exposure
to the glass-bound collagen fibrils, platelets were more insensitive to the secondary
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agonist TXA2 reducing to the total accumulation of platelets. Results are qualitatively
consistent with dose response data collected using the previous 8-channel device
design with syringe pump withdrawal for fluid delivery [27].

Figure 2.6: Aspirin Effect on platelets in PPACK blood
Dose response for N=1 donor for acetylsalicylic acid (Aspirin) added from DMSO solution to
blood ex vivo, perfused at 7.5 mmHg, or approximately 100 s-1 initial . Results consistent with
previously published results from original 8-channel device with perfusion performed by syringe
pump
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2.4 Discussion
The development of in vitro microfluidic assays has enabled studies on various
aspects of hemostasis and thrombosis, including evaluation of disease states, geometric
pathologies, drug action, and many others [27,30,31,57]. In cases where samples of
interest must be obtained outside the lab, as in the case of patient studies, the need to
either transport pre-prepared microfluidic devices or the blood itself causes logisitical
difficulties in terms of timing and stability. Devices that are amenable to use on-site in
any location and by untrained personnel would therefore present a significant
improvement in this regard. The device described in this work addresses several of the
major difficulties in operation of PDMS microfluidic devices, while retaining their general
utility.
A critical step in the operation of PDMS microfluidic devices for hemostasis
testing is the pre-filling of the devices with buffer designed to both passivate the wetted
materials against platelet adhesion and contact activation, and to ensure smooth
perfusion of blood through the devices without the pinning of air bubbles. In some
devices, this is done by manually pipetting a BSA buffer into inlet wells, drawing through
the outlet with a syringe, and then removing the excess from the inlet wells prior to blood
addition. This is both labor intensive and prone to significant error, as PDMS in relatively
hydrophobic and will tend to pin large bubbles in the corners of inlet wells. Further, the
number of steps in the procedure scales with the number of channels, making a
translation of this paradigm to next generation devices more and more problematic. The
newly designed, in-line 8-channel PDMS device addresses this issue by addition of a
dedicated priming line, making the process facile and one-step. Volume of priming buffer
can be allocated such that no excess is accumulated in the inlet wells, eliminating the
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need for removal of excess fluid from the inlet wells. Another area of improvement for
the new design is liquid handling for transferring blood into the device. Rather than
requiring independent pipette actions for each of the channels, arrangement of the inlet
wells along a single line with 9 mm spacing enables the use of a multi-channel pipette to
fill all 8 wells simultaneously. This both streamlines the process and reduces the
likelihood of bubble entrapment.
Several aspects of the device described in this work are novel, and their
properties are captured in patent application US62/645,525, included in its entirety in
Appendix II.
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CHAPTER 3 : SCALABLE MANUFACTURE OF A DISPOSABLE,
STORAGE-STABLE, EIGHT-CHANNEL MICROFLUIDIC DEVICE
FOR RAPID TESTING OF PLATELET, COAGULATION, AND
DRUG FUNCTION UNDER WHOLE BLOOD FLOW
3.1 Introduction
One of the key functions of blood in the human body is to maintain hemostasis—
that is, to maintain circulation and arrest leakage at the site of an injury when it occurs.
An injury event exposes tissue factor and collagen from the vessel that stimulate clot
formation over the damaged area. This is achieved by the activation and accumulation of
platelets into a plug, and the formation of a mesh of fibrin generated from the
polymerization of the circulating plasma protein fibrinogen, which is carried out by the
coagulation cascade. In order to monitor and assess this function of blood, various
assays exist that detect either the presence or action of either platelets or fibrin or both.
Over the last decade, microfluidic assays have proven to be an effective
diagnostic tool for assessing platelet function and coagulation, creating relevant flow
hemodynamics, while utilizing a minimal volume of blood [24–27,29,31,58–63].
Polydimethylsiloxane (PDMS) is a popular choice for devices in these assays due to the
speed and ease of fabrication, re-usability, and fidelity to the design geometry [64,65].
PDMS enables the replication of flow channel geometries on the scale of tens of
micrometers, allowing physiological shear rates while utilizing only microliters of blood.
Flow parallelization, as demonstrated in the previously developed eight-channel
microfluidic device, allows for testing varied experimental conditions simultaneously,
such as dose–response testing of platelet or coagulation inhibitors in a single donor
blood sample [26,27,53,66]. More specialized single-thrombus devices have also been
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demonstrated, which incorporate trans-thrombus transport into the assay [29,31,61]. The
versality of the microfluidic platform allows for variations in the particular thrombogenic
surfaces and flow delivery methods used in each assay, providing more complete
recreation of thrombotic and hemostatic processes [24,59,61,62,67,68].
Although PDMS devices are reliable and easy to construct, they are typically only
transiently sealed, often with vacuum or clamping, and need to be assembled prior to
each use. Several studies have been performed with blood samples from clinical
cohorts, but these experiments require a highly trained individual to perform them.
Challenges associated with preparing devices ahead of time complicates experimental
timing and typically necessitates the use of strong anti-coagulants [25,27,63,69].
Furthermore, traditional soft lithography methods for producing PDMS devices from
silicon masters do not have an obvious method of production scale-up. Although PDMS
microfluidic devices offer significant design freedom and enable novel observations in
thrombosis and hemostasis research, their application to the clinical environment
remains an existing challenge.
Several point-of-care (POC) diagnostic techniques exist for assessing patient
anti-coagulation status and platelet function, but many have very specific readouts, and
none have demonstrated themselves as the clinical standard for hemostasis diagnostics.
Thromboelastography and rotational thromboelastometry (TEG/ROTEM) are both POC
viscoelastic tests that rapidly produce data from whole blood samples over a 30–60 min
test [70]. Viscoelastic methods emerged over 50 years ago and are beginning to find use
in the field of trauma surgery. Viscoelastic methods monitor a whole blood clot but do not
capture the impact of flow in a physiological way, due to their closed-system nature.
Furthermore, viscoelastic measurements do not detect specific molecular entities

34

(platelet receptors, fibrin) and only recently entered the stage of POC use [15,70]. The
Platelet Function Analyzer 100 (PFA-100) is a microfluidic assay that uses pressure
sensors to detect the occlusion of an aperture coated with collagen and adenosine
diphosphate (ADP), with the time to reach occlusion as the primary metric. This test is
limited to the platelet function, however, and operates at very high shear rates (>5000
s−1), limiting its ability to capture physiological flow conditions and making the assay
quite sensitive to variations in the von Willebrand factor (VWF) [71]. A second
microfluidic technique that has been under recent investigation is the total thrombus
formation analysis system (T-TAS). This assay has the advantage of operating at
physiological shear rates and in an open system, but generates only a single clot per
chip, has shown a poor correlation with direct oral anti-coagulant (DOAC) doses, and
has poor agreement with the more established thromboelastographic methods [71,72].
This study used validated flow experiments and reagents from PDMS microfluidic
techniques and deployed an injection molded chip to create a versatile technology for
medical professionals at the bedside [24–26,60,69]. A POC microfluidic device needs to
(1) utilize small volumes (<1 ml) of whole blood, (2) have a scalable production method,
(3) be simple to prime and operate by non-expert users, (4) retain uniform flow behavior
across all test conditions, (5) be storage stable in a prepared state, and (6) have a total
experimental footprint suitable for benchtop use. Thus, by retaining the critical geometric
parameters of prior PDMS devices, but manufacturing the parts via injection molding,
and streamlining the operational procedures, a new microfluidic device serves clinical
studies in thrombosis and hemostasis testing (1). Stable sealing and stable reagents are
also required [73,74]. We demonstrate a storage stable device that can be rapidly used
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with a fresh whole blood sample in a multiplexed eight-channel readout of platelet and
fibrin function.

3.2 Materials and Methods
3.2.1. Device design and flow simulation
A previously published eight-channel microfluidic design deployed in PDMS
devices was translated to fit on a 75.5 mm by 25.5 mm standard microscope slide
footprint, to facilitate translation to an injection molding platform Figure 3.1A. SolidWorks
2018 (Dassault Systèmes) was used to generate a full 3D model of the device flow
paths. Steady state flow simulations (COMSOL 5.3a) were performed to verify uniformity
of flow rates in each of the channels and to verify wall shear rates (Newtonian viscosity
= 4 cP). To experimentally verify flow rate uniformity, solutions of FITC-conjugated flow
cytometry beads (Spherotech) with four distinct peaks were added symmetrically to each
of the four wells on both sides of the chip. The bead solutions were perfused through the
device for 10 min and the effluent was collected and analyzed on an Accuri C6 flow
cytometer (BD Biosciences). These results were compared with a uniformly pre-mixed
control sample of all bead populations. Additional simulations were performed to monitor
flow rate, pressure drop, and wall shear rate as a simulated clot formed and reduced the
channel cross section.
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Figure 3.1: Injection molded 8-channel device and priming
(a) Schematic of injection molded chip with eight channels designed to have equal flow when
applying a negative pressure at outlet. (b) Visual demonstration of priming, where priming fluid
(green) injected in the dedicated priming inlet arrives at each inlet port and the outlet port
simultaneously. (c) Blood added to inlet wells displaces priming fluid when a negative pressure
applied at the outlet.

3.2.2. Device preparation and flow control
Experimental chips were assembled from pre-made, injection-molded cyclicolefin-copolymer plastic components (ChipShop) with flow-paths molded into them as
rectangular troughs. Type I equine fibrillar collagen (Chrono-Log) and lipidated tissue
factor (TF) (Siemens) were coated as a 250 μm wide strip to a sheet of an optically clear
substrate with an adhesive (ThorLabs), using a PDMS patterning device as previously
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described [26]. The adhesive sheet was then used to form the fourth wall of the
rectangular cross section (Supplemental Figure 1). Blood was perfused through the
completed chips by applying a negative pressure at the outlet using a KPV14A miniature
diaphragm vacuum pump (Koge Electronics) with a USB-controlled pressure controller
(Fluigent). The pressure was calibrated to yield a centerline velocity of 0.004 m/s and an
initial flow rate of 14 μl/min, corresponding to an initial wall shear rate of 200 s−1. The
effluent blood from the device was captured in a liquid trap with a custom tubing adapter
(Fluigent).

3.2.3. Blood collection
Blood was collected from consenting healthy donors self-reporting as free of any
medications for at least 10 days. Blood was drawn via venipuncture into the corn trypsin
inhibitor (CTI, Haematologic Technologies) to a final concentration of 4 mg/dl (40 μg/ml),
in order to prevent Factor XIIa activation prior to the experiment, while allowing tissue
factor-initiated thrombin generation in the surface test region of coated collagen/TF. All
procedures were conducted in accordance with protocols approved by the University of
Pennsylvania's Institutional Review Board and the Declaration of Helsinki.

3.2.4. Platelet and fibrin detection during clotting
Platelets were labeled in whole blood by the addition of a non-function blocking,
AlexaFluor 488-conjugated anti-CD61 molecule (Bio-Rad Laboratories), while fibrin was
quantified by the addition of AlexaFluor 594-conjugated human fibrinogen (Life
Technologies). Chips were mounted on a three-color, LED-based Lumascope 620
(Etaluma) benchtop epifluorescence microscope with a 2.5× objective and primed with
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150 μl of a solution 0.5% bovine serum albumin (BSA) in HEPES-buffered saline (HBS).
A volume of 35 μl of blood was added to each of the eight inlet wells, with a negative
pressure applied to the single outlet to initiate flow at t = 0. Fluorescence images were
captured at 10 s intervals for green and red LED channels to obtain kinetic data for
platelet and fibrin accumulation. Image sequences were analyzed with ImageJ to
calculate the average pixel brightness of a 200 μm by 200 μm region center within each
clot zone, in order to exclude sidewall effects of the rectangular channels.

3.2.5. Stability testing
In order to assess the ability of collagen and tissue factor reagents to retain
activity over time, chips were prepared as described and then stored in a 4 °C
refrigerator in an air-tight chamber with a desiccant. After 6 months, chips were removed
from the chamber and tested in the microfluidic assay. For comparison, a second device
prepared immediately before use was also tested with the same blood sample.

3.2.6. DOAC testing
To test the effects of DOACs added ex vivo, dry rivaroxaban or apixaban
(SelleckChem) were dissolved in DMSO (20 mM stock solution) and diluted to 100 μM in
HBS, then further diluted for final concentrations of 0.05, 0.2, 0.5, and 5 μM after the
addition of 90 μl of whole blood in separate microcentrifuge tubes. HBS was added to
each tube such that the total volume of drug solution and additional buffer was 10 μl in
each, to ensure the hematocrit remained consistent across all conditions and whole
blood composed 90% of the final volume.
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To compare the Xa inhibitors with a direct thrombin inhibitor, Dabigatran (active
form) (SelleckChem), dry powder was dissolved in a solution of 10% trifluoroacetic acid
in de-ionized water, to an initial concentration of 40 mM. This stock was then diluted to
100 μM in HBS and again then further diluted for final concentrations of 0.05, 0.2, 0.5,
and 5 μM after the addition of 90 μl of whole blood in separate microcentrifuge tubes.
The platelet and fibrin accumulation assay described above was then performed for
each DOAC, with one well of the control condition (no drug), one well of 5 μM drug, and
two wells each for the remaining concentrations. Chips were run immediately after
DOAC dosing of blood.
To evaluate the extent that DOAC reversal can be observed using this assay,
Andexanet Alfa (Portola Pharmaceuticals) was added to whole blood containing
Apixaban. Samples were prepared for 0.02 μM Apixaban, 0.02 μM Apixaban with a 1:1
molar ratio of Andexanet Alfa, and 0.02 μM Apixaban with a 1:5 molar ratio. For each
chip, two wells each were allocated for the control condition (no drug, no reversal agent),
and two each of the aforementioned drug combinations. Chips were run immediately
after dosing of blood.

3.2.7. Statistical analysis
Statistical significance was calculated for an unpaired t-test, using GraphPad
Prism (GraphPad Software). Shaded error regions on plots represent the standard
deviation from the mean. Coefficients of variation (CV) are reported for the 400 s time
points in each experiment. Concentrations for 50% inhibition (IC50) were calculated using
the t = 400 s time point for each concentration, with the “log(inhibitor) vs response” 3-
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parameter routine in Prism, with a fixed baseline at the fluorescence intensity noise level
of the microscope (FI = 2.5 A.U.)

3.3 Results
3.3.1. Injection-molded, disposable chip
A previously described eight-channel PDMS device was successfully converted
to an injection molded 1 × 3 in.2 microscope slide footprint. The 60 μm height × 250 μm
width of each channel was retained from the original device. The inlet well locations
were altered to be linearly oriented, with 96-well spacing for convenient pipetting.
Serpentine elements were added to the flow-paths such that the fluidic resistance of
each channel was identical, ensuring that the flow rate through each channel was
identical (Figure 3.1A). The final chip (up to 5 chips at a time) was bonded with manual
pressure (single pass with moderate pressure) applied by “ink” roller, a processing step
highly amenable to roller automation. Failure of bonding indicated by fluid leakage was
never observed in manufacturing runs up to 100 chips. An additional port was added to
the design for back-priming of the device with 0.5% BSA for the passivation of the
wetted surfaces to minimize FXIIa generation and platelet adhesion (Figure 3.1B). Extra
flow resistance was added to the converged outlet channel such that priming fluid was
evenly split toward the inlet channels and the single outlet port. Priming was achieved by
injecting 150 μl priming fluid with a 1 ml plastic syringe through a luer check valve
(Supplemental Figure 1).
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3.3.2. Flow simulations
Uniformity of flow was verified by both simulation (Supplemental Figure 2) and
experiment (Supplemental Figure 3), ensuring identical hemodynamics in each lane. In
order to characterize the changes to the flow as experiments progress for a new fluid
delivery method, COMSOL simulations were performed for an inlet pressure of 16 000
Pa (120 mmHg) over each inlet and an outlet pressure of 0 Pa (atmosphere) in order to
match the total ΔP to the negative pressure typically applied to the outlet in experiments
(160 mbar vacuum). Pressure was maintained as constant, as the hydrostatic pressure
is a negligible contribution (∼20 Pa) and, therefore, changes in inlet well height do not
alter the value meaningfully. Furthermore, the reservoir hydrostatic head never drove
blood flow spontaneously in the primed chip prior to operation. Blood was modeled as a
Newtonian fluid with a density of 1060 kg/m3 and a viscosity of 4 cP, as blood's nonNewtonian properties are considered unimportant for shear rates in excess of 100
s−1[75]. The impact of thrombus growth on the overall flow was modeled by enforcing a
reduction in the lumen area of the channel over the 250 μM × 250 μM collagenintersection region in discrete steps and running a separate flow simulation for each
thrombus height (Figure 3.2A). This height restriction was represented as an occlusion
fraction between 0 and 1. The flow rate, pressure drop across the clot region, and wall
shear rate at the top surface of the thrombus were calculated for occlusion fraction
(Figure 3.2B and C). In all experiments, clot height changes during the experiment if
platelets are functional, causing the fluidics to evolve. When full occlusion is reached,
this corresponds with platelet signal reaching its maximal value and, in this way, the
instantaneous clot height relative to the channel height can be interpreted by the
fluorescence intensity in proportion to the maximal value [61]. Although experiments for
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this study were not run to full occlusion, this value has been observed as ∼60 A.U. for
the lighting conditions and label concentrations used in this work.

Figure 3.2: Flow Simulations for injection molded chip
(A) 2D side view of the focal region of a single channel from a 3D model of chip. (B) Volumetric
flow rate as a function of occlusion fraction (h/60), for a constant outlet vacuum pressure. (C)
Pressure drop across the clot as a function of occlusion fraction. (D) Shear rate at the top surface
of the clot as a function of clot height.

For experiments with <70% occlusion (∼70% maximal platelet FI), the pressure
drop is essentially constant, as is the flow rate, however, the wall shear rate increases
as shown in Figure 3.2. As the clotting event approaches full occlusion, the wall shear
rate on the exposed surface of the clot becomes pathological reaching 20 000 s−1, a
shear rate sufficient to extend and deposit von Willebrand factor (VWF) and mediate
shear induced platelet activation (Figure 3.2D) [61,76].
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3.3.3. Healthy whole blood clotting on collagen and tissue factor
In order to establish the baseline performance of the newly designed device,
whole blood from N = 10 healthy donors was perfused through devices prepared as
described at 200 s−1, with all n = 8 channels running simultaneously (Figure 3.3A and B).
For the 10 healthy donors (8 male), the platelet signal measured by image analysis of
immunofluorescence showed an average interdonor CV of 30%, with the fibrin signal
displaying a CV of 22%. No differences were observed between the platelet or fibrin
signals and the specific inlet well from which the blood originated, verifying that the flow
in each channel was identical.

Figure 3.3: Healthy Donor for injection molded chip
Average platelet intensity (a) and fibrin intensity (b) vs time for N = 10 donors, and n = 8 clots
per donor for a constant outlet pressure yielding an initial wall shear rate of 200 s−1. (c)
Fluorescence microscopy images for platelets (AF488 CD-61) and fibrin (AF594-conjugated
human fibrinogen) at t = 400 s.
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3.3.4. Chip stability
Prefabricated microfluidic chips retained activity when stored at 4 °C for 6 months
in dry conditions when tested at the same 200 s−1 venous condition as previously
described. Both platelet and fibrin signal showed similar response when compared to a
chip prepared immediately prior to use (NS, p > 0.05), indicating minimal degradation of
the collagen or tissue factor reagents during the storage period (Figure 3.4).
Interestingly, chips stored at room temperature showed significant reduction in the
platelet signal after less than one week, likely indicating loss activity in the GPVI binding
domains of the collagen.

Figure 3.4: Chip storage stability at 4 oC
Comparison of a chip used immediately after preparation (day 1) and a chip used 6 months after
preparation (stored at 4 degrees Celsius in a desiccated chamber) for platelet (a) and fibrin (b)
intensity. Data for N = 1 donor, and n = 8 clots per chip, where blood is perfused with constant
outlet pressure yielding an initial wall shear rate of 200 s−1. No significance was detected in the
fresh vs stored chips for either platelets or fibrin (p > 0.05)
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3.3.5. DOAC detection
To assess the ability of our assay to determine the anti-coagulation status of
blood sample, the platelet and fibrin accumulation assay was run at four concentrations
of rivaroxaban. For N = 3 healthy donors, a strong dose dependent response in fibrin
signal was observed for each DOAC added to blood ex vivo, yielding an IC50 of 120 nM
for rivaroxaban and apixaban, and 60 nM for dabigatran [Figure 3.5C,F, Figure 3.6C].
The lowest concentrations of rivaroxaban, apixaban, and dabigatran (50 nM) all showed
a statistically significant difference in fibrin signal at 500 s (p < 0.01). The platelet
deposition signal had minimal correlation with drug concentration, indicating that in this
assay, collagen activation of platelet GPVI dominated the platelet deposition.

Figure 3.5: Xa inhibitor Dose Responses in healthy donors
Fluorescence data for whole blood treated with Factor Xa inhibitors rivaroxaban (a)–(c) and
apixaban (d)–(f), showing limited platelet response (a) but a strong dose-dependent response for
fibrin signal (b). (c) and (f) Log[inhibitor] vs fibrin intensity indicating an IC50 of 120 nM for both
inhibitors in this assay. A statistically significant difference in fibrin signal was observed at 500 s
for both drugs (*p < 0.01).
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Dabigatran was significantly more potent than either of the factor Xa inhibitors in
these assays for fibrin signal (Figure 3.6). Controls run with TFA alone confirmed that
this difference was not due to the action of the vehicle solvent but rather the drug itself.
Platelet signal was similarly limited in response to drug concentration for each DOAC.

Figure 3.6: Dabigatran Dose response
Fluorescence data for whole blood treated with Factor IIa inhibitor Dabigatran, showing limited
platelet response (a) but a strong dose-dependent response for fibrin signal (b), and micrographs
of the same at t = 400 s (d). (c) Log[inhibitor] vs fibrin intensity indicating an IC50 of 60 nM in this
assay. A statistically significant difference in fibrin signal was observed at 500 s (*p < 0.01).
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3.3.6. DOAC reversal
To evaluate the ability of the assay to detect reversal of DOAC drug action in whole
blood, platelet and fibrin accumulation assays were run for three combinations of
apixaban and the mutant inactive factor Xa molecule Andexanet Alfa. For N = 3 healthy
donors, the anticipated ∼50% inhibition of fibrin signal was observed for 0.2 μM apixaban
alone, which was completely reversed to control behavior by an equimolar ratio of

Andexanet Alfa [Figure 3.7B]. A 1:5 ratio of Andexanet Alfa to apixaban yielded partial
restoration of fibrin signal. For all combinations of drugs, no clear trend was observed in
the platelet signal [Figure 3.7A].

Figure 3.7: Reversal Data for Xa-inhibitors added in vitro with Andexanet Alfa
Fluorescence data for whole blood treated with 200 nM Factor Xa inhibitor apixaban with and
without mutant inactive factor Xa molecule Andexanet Alfa (Andexxa) as a reversal agent.
Platelets (a) show no dependence on either drug or reversal agent, whereas fibrin (b) is partially
inhibited by apixaban, but is recovered completely by an equimolar ratio of Andexanet Alfa, and
partially recovered by 1:5 deficit of Andexanet Alfa.
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3.4 Discussion
Custom microfluidic devices are widely used in thrombosis/hemostasis research
laboratories for the interrogation of small blood samples under diverse hemodynamic
flows and real time multi-color imaging. PDMS devices have allowed the study of
hemophiliac blood, neonatal blood, and trauma patient blood [25,69,77]. Additionally
drugs such as COX inhibitors, P2Y12 inhibitors, reFVIIa, and polyphosphate inhibitors
have been studied using microfluidics [25–27,53,60,66]. However, such PDMS devices
are difficult to use in the emergency room (ER) or bedside point-of-care (POC)
diagnostics due to obstacles in (a) manufacturing scale-up and (b) ease of operation.
Using only 250 μl of whole blood, this single use and disposable chip allowed
eight independent clotting events to proceed simultaneously under venous shear rates,
while monitoring platelet deposition and fibrin production over time. A chip design was
developed to demonstrate (1) the ability to injection mold small features into plastic; (2)
successful collagen/TF microprinting; (3) successful mechanical bonding of the chip
layers; (4) successful priming fluidics; (5) collagen/TF integrity during bonding; (6)
retention of collagen and tissue factor activity in a dry state at 4 °C; and (7) blood
compatibility. Operation of the chip required eight-channel pipetting of blood into reagent
wells (detectors, inhibitors, etc.) and then onto the chip, suitable for manual or
automated pipetting.
Injection molding enables this chip design to be manufactured at scales of
thousands per run, rather than the tens per day possible by PDMS replica molding, while
maintaining a low cost per chip. By altering the flow delivery to a constant negative
pressure applied through a dry tubing line, the assay preparation process has been
simplified by removing the need for a prefilled syringe to mount in a syringe pump.

49

Furthermore, clots formed under a constant outlet pressure show reduced ballistic
embolization of near-occlusive clots, compared to clots formed under constant flow rate
perfusion.
Several alternative microfluidic sealing methods exist to create multilayer
devices, such as ultrasonic welding, solvent bonding, and thermal bonding [78–80]. The
need to retain the activity of biological reagents within the chip through sealing limits
options, however, and was verified in this study. The use of collagen pre-patterned in a
localized, ready-to-use dried state in this format offers a unique advantage to this new
device. In other assays, alternative agonists such as adenosine diphosphate are used
(TEG-6S) or collagen is typically added from a solution either stored refrigerated or
frozen (aggregometry) [81]. The pressure sensitive adhesive used in this study provided
a robust seal that held for >6 months and showed no observable off-target platelet
adhesion or fibrin formation, when used with a passivating BSA priming solution. The
new device retained uniform behavior channel to channel, as indicated by the 10%
intrachip CV. In addition, manufacturing is scalable to mass manufacturing levels of 102–
103 chips per run.
More than 4 × 106 U.S. patients are currently prescribed DOACs for diseases
such as atrial fibrillation (A-fib) and deep vein thrombosis (DVT) [37]. With increasing
use of DOACs comes a corresponding increase in patients at risk of bleeding, making
monitoring patients for bleeding risk an ever more critical task. There does not exist,
however, a reliable, standardize laboratory method of monitoring the anticoagulation
status for DOAC patients in clinical settings, a need that the assay described in this work
may help address. Expected values for drug concentration (Cmax and Ctrough) levels for
patients on dabigatran (150 mg twice daily), rivaroxaban (20 mg once daily), and
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apixaban (5 mg twice daily) are known from plasma measurements, providing a range of
interest for detection [82]. Typical rivaroxaban plasma concentration ranges between
approximately 115 and 320 nM, depending on the dosage, a range that is within the
detectable range of the described assay, based on the measured 120 nM IC50 [83]. The
IC50 for rivaroxaban has previously been reported at lower values (21 nM) in other
assays, by directly quantifying Factor Xa activity rather than correlating with fibrin signal,
in assays carried out in plasma under static conditions [84]. The ISTH recommended
maximum rivaroxaban concentration prior to urgent intervention is 30 ng/ml (∼70 nM) for
patients at risk of bleeding, where Factor Xa inhibitor reversal agents are recommended
at all higher concentrations [85]. With 50 nM rivaroxaban detectable in the assay
reported (corresponding to ∼22 ng/ml), the device presented may be useful in

quantifying DOACs to help assess patient risk relative to ISTH guidelines. Comparable
detection ranges have been reported for the TEG-6s (30 ng/ml), but without the ability to
run multiplexed assays to the same extent, the ability to independently monitor platelets
and fibrin, and without physiological flow conditions [86]. With the high cost of Factor Xa
reversal agents (>$50 000 per full dose), the ability to provide fast, point-of-care
measurements of a patient's current inhibition levels could potentially improve decision
making for management of bleeding patients [87]. In addition, since the assay is
quantifying fibrin rather than Xa activity, IIa inhibitors can be detected without modifying
the assay, as shown in Figure 3.6, unlike in TEG assays.
In addition to patients on DOACs, traumatic injury patients present another case
where monitoring current anticoagulation status is critical. Trauma is the leading cause
of death in the U.S. and accounted for approximately 1.7 × 106 hospital visits a year for
the period of 2000–2011 and can lead to platelet dysfunction and bleeding risk from
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trauma induced coagulopathy (TIC) [88]. The ability to independently monitor platelet
and fibrin signal may also help differentiate DOAC anticoagulation and trauma induced
coagulopathy (TIC), as TIC is typically associated with platelet hypofunction as well as
coagulation dysfunction, which has been previously observed in previous microfluidic
assays [52,69]. Direct inhibition of Factor Xa, contrastingly, does not show a significant
impact on platelet signal in this assay, except the highest concentrations—far in excess
of therapeutic doses [Figure 3.5A and D]. Other currently utilized methods such as
prothrombin time (PT) and activated partial-thromboplastin time (aPTT) are not able to
differentiate DOAC anticoagulation and dysfunction due to TIC [87]. Although sensitivity
to DOACs has been demonstrated in TEG, the single “amplitude” output signal similarly
makes distinguishing between platelet and coagulation dysfunction more ambiguous
without performing additional comparative experiments in the presence of platelet α2bβ3
inhibitors [89].
Detection of the action of a reversal agent in a DOAC measurement assay is
critically important to distinguish drug-related anticoagulant behavior from disease or
trauma associated coagulopathy. The ability of the microfluidic assay described in this
work to detect the action of reversal agent on therapeutic dosages of a DOAC using less
than 0.5 ml of blood, and ∼1 μg of reversal agent could provide utility in bedside
applications for bleeding risk assessment.

The device defined in this study allows rapid POC use for the multiplexed assay
design (8 channels ×2 or 3 colors), ideal for blood phenotyping, drug dose–response,
and risk assessment.
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CHAPTER 4 : RAPID DETECTION OF DOACs IN DVT PATIENTS
USING A SINGLE-USE MICROFLUIDIC CHIP UNDER WHOLE
BLOOD FLOW

4.1 Introduction
Over the last decade since their inception, utilization of Direct Oral
Anticoagulants (DOACs) targeting either thrombin (dabigatran) or factor Xa (apixaban,
rivaroxaban, edoxaban) has grown significantly for indications such as deep vein
thrombosis (DVT) and atrial fibrillation (Afib) [36,90,91]. Compared to the previously
ubiquitous Vitamin K antagonists, DOACs have been shown to have a more rapid onset
of action and reduced risk of adverse bleeding events such as intracranial hemorrhage,
while having superior or equivalent endpoint efficacy, although in some cases an
increased risk of less severe gastrointestinal bleeding has been reported [36,92–94].
Owing to these advantages and the lack of requirement for routine monitoring, DOAC
prescription claims for diseases like Afib have increased significantly at the expense of
vitamin K antagonists (VKA) such as warfarin [93,95,96].
Although routine monitoring is not required for DOAC use, particular clinical
scenarios may require diagnostic information on DOAC action, such as traumatic injury
or bleeding, perioperative management, possible drug interactions or overdose, or
suspicion of patient non-adherance to dosing regimes [93,97]. In situations such as
these, standard laboratory coagulation tests such as PT/INR and aPTT provide variable
information based on the specific reagents and instruments used and are not suitable to
make quantitative measurements; at trough plasma concentration levels, these tests can
produce results which appear as ‘normal’ blood samples with no drug present [96,98,99].
Further, these assays cannot distinguish between thrombin and Xa inhibitors. Assays
53

specifically designed for these DOACs, such as calibrated anti-Xa assays, can provide
greater insight and even quantitative information on drug concentrations, but are slow
and not widely available. To date, only one test has been authorized by the FDA for
measurement of DOACs, the HemosIL Liquid Anti-Xa test kit, for apixaban.
Recent years have seen an influx of new potential POC devices being
developed, although none has shown clear superiority for detection of drug presence, or
demonstrated quantitation of drug concentrations [49–51,100,101]. Therefore, the need
for fast, cost effective methods to detect and quantify DOACs, particularly in emergency
situations remains. To address these needs we have developed a whole blood
microfluidic assay for detection of factor Xa inhibitors in DVT patients utilizing small
amounts of Xa-inhibitor reversal agent (~0.5 μg). We evaluated the assay for detecting
the presence of DOAC action, and also for quantitation of drug concentration and
compared against LC/MS measurements of plasma samples from the same patients.

4.2 Materials and Methods
4.2.1. Device design
A previously published eight-channel design used for injection molded devices was
reoriented such at all 8-channels were in a single line [102]. In order to maintain
equivalent volumetric flow rates for fluid withdrawal through a single outlet, the fluidic
resistance (Equation 4.1) was held constant for each of the 8 channels.
Eqn 4.1
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In order to maintain the height and width of each channel as constants to avoid
causing potential differences in platelet margination, hematocrit or shear rate rate in
each of the channels, length was required to remain constant from each inlet well to the
focal imaging region. Serpentine flow paths were added for the wells closest to the
imaging region in order to maintain equivalent resistance (Supplemental Figure 4). 2D
steady state flow simulations (COMSOL 5.3a) were performed to verify uniformity of flow
rates in each of the channels.

4.2.2. Device preparation and flow control
Microfluidic chips were assembled from injection-molded cyclic-olefin-copolymer
plastic components (ChipShop) as described previously [102]. Briefly, type I equine
fibrillar collagen (Chrono-Log) and tissue factor (TF) (Siemens) were coated as a 250 μm
strip to an acryllic adhesive substrate (ThorLabs). The adhesive sheet was then
laminated to the injection molded part to complete the device. Blood was perfused
through the completed chips by negative pressure at the outlet from a KPV14A miniature
diaphragm vacuum pump (Koge Electronics), maintaining constant pressure with a
controller (Fluigent) operated via usb communication with a laptop. The pressure was
calibrated with EDTA anticoagulated blood to yield an initial flow rate of 14 μl/min,
corresponding to an initial wall shear rate of 200 s−1. The effluent blood from the device
was captured in a 15 mL centrifuge tube liquid trap with a custom tubing adapter
(Fluigent).
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4.2.3. Blood collection
Blood was collected from either consenting healthy adult donors or DVT patients
on either apixaban or rivaroxaban, in accordance with protocols approved by the
University of Pennsylvania's Institutional Review Board and the Declaration of Helsinki.
For patients, blood was drawn via venipuncture into untreated ‘no additive’ vacutainers
(BD) and promptly transferred to 15 mL centrifuge tubes containing corn trypsin inhibitor,
to a final concentration of 4 mg/dL (40 μg/mL). All patient blood was collected on site at
the Hospital of University of Pennsylvania, and then transported prior to analysis, with
approximately 10-20 minutes between collection an experimentation. For healthy
donors, blood was collected into 3 mL luer-lock syringes containing CTI to a final
concentration of 40 μg/mL.

4.2.4. Platelet and fibrin detection during clotting
Platelets were labeled in whole blood by the addition of a non-function blocking,
AlexaFluor 488-conjugated anti-CD61 molecule (Bio-Rad Laboratories), while fibrin was
quantified via addition of AlexaFluor 594-conjugated human fibrinogen (Life
Technologies). Chips were mounted on a three-color, LED-based Lumascope 620
(Etaluma) benchtop epifluorescence microscope with a 2.5× objective, and primed with
150 μl of a solution 0.5% bovine serum albumin (BSA) in HEPES-buffered saline (HBS,
20 mM HEPES, 160 mM NaCl, pH 7.4). A volume of 40 μl of blood was added to each of
the eight inlet wells, with a negative pressure applied to the single outlet to initiate flow at
t = 0. Fluorescence images were captured at 10 s intervals for green and red LED
channels to obtain kinetic data for platelet and fibrin accumulation for a total of 15
minutes. Image sequences were analyzed with ImageJ to calculate the average pixel
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brightness of a 200 μm by 200 μm region center within each clot zone, in order to
exclude sidewall effects of the rectangular channels.

4.2.5. DOAC reversal and detection
For N=3 healthy donors, Andexanet Alfa (AA, Portola pharmaceuticals) was
added to a final concentration of either 50 or 300 nM, in order to assess the impact on
blood without inhibitor present. For N=8 patients, in order to simulate patient blood
without the presence of the anticoagulant, small amounts of AA were added to four of
the eight wells for each patient: two wells with a final concentration of 300 μM and two
wells with a final concentration of 50 μM (Supplemental Figure 5). All AA was stored as a
10 mg/mL solution in buffer at -80 °C and thawed and diluted as needed. To provide a
‘fully inhibited’ response, additional Xa inhibitor, either rivoraxaban or apixaban, to the
match the drug already in the patient blood, was added to two of the channels for each
patient. Rivaroxaban or apixaban (SelleckChem) were dissolved in DMSO (20 mM stock
solution) and diluted to 100 μM in HBS, then added to a final concentration of 5000 nM
to two of the wells. Finally, the remaining two wells were run as collected from the
patient. For all wells, make-up HBS volume was added such that whole blood comprised
exactly 90% of the final volume of the mixture, in order to ensure the hematocrit
remained constant for each condition

4.2.6. DOAC concentration prediction
In order to predict the concentration of DOAC in the patients systems, the relative
fluorescence intensity of the patient’s unmodified blood and the high reversal agent
condition were compared. These were then scaled to a previously measured dose
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response of the fibrin fluorescence intensity to apixaban and rivoraxaban added in vitro
to healthy donor whole blood (Figure 3.5), according to Equation 4.2, where any signal in
the 5000 nM anticoagulant condition is considered as purely background signal.
Eqn. 4.2

FI measured =

( FI patient −FI HighAC )
∗(FI Dose Response max−FI Dose Response Min )+ FI Dose Responsee Min
( FI 300 nM −FI HighAC )

The resulting FImeasured from eqn. 4.2 was set as the ouput of the 3 parameter Sigmoid fit
of the IC50 curve from the in vitro dose response model of the relevant Xa inhibitor
(Figure 3.5), of the form
Eqn. 4.3

FI measured =FI Dose Response Min +

(FI Dose Response Max −FI Dose Response Min )

(1+ ICX50 )

where a Hill slope of 1 is assumed, and solving for X yields the concentration that would
give the FImeasured obtained for each patient, mapped to the in vitro scale.
4.2.7. Statistical analysis
Statistical significance was calculated by two-tailed t-test, using GraphPad Prism
(GraphPad Software). Shaded error regions on plots represent the standard deviation
from the mean. For evaluation of coefficients of variation, fluorescence intensity at 400 s
was selected. Receiver operator characteristic curves were calculated using the ROC
analysis tool in GraphPad Prism for a >95 confidence interval with the Wilson/Brown
method. For each scatter dot plot, fluorescence intensity are reported for a single timepoint from the 15 minute experiment; either the 500 second time-point, or at the time
where the average of the 300 nM reversal agent condition was at 83% of its maximal
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value over the full 15 minutes. Where indicated, data for each patient is normalized by
the maximum value among the lanes where the 300 nM AA is used.

4.3 Results
4.3.1. Healthy whole blood clotting on collagen and tissue factor for new device design
To confirm the performance of the newly designed 8x1 chip, whole blood from N
= 5 healthy donors was perfused through devices prepared as described above at 200
s−1, where perfusion occurs through all n = 8 channels simultaneously by application of
negative pressure at the outlet (Figure 4.1, A and B). Across all 5 healthy donors, the
platelet signal measured by image analysis of immunofluorescence showed an average
interdonor CV of 25%, with the fibrin signal displaying a CV of 20%. No differences were
observed between the platelet or fibrin signals and the specific inlet well from which the
blood originated, verifying that the flow in each channel was identical. For healthy donors
with Andexanet Alfa added ex vivo, no effect on fibrin signal was observed at either
concentration, suggesting there are no major off-target effects at the concentrations
utilized in this work (Figure 4.2).
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Figure 4.1: Healthy adult whole blood using 8 by 1 COC chip design
Average platelet intensity (A) and fibrin intensity (B) vs time for N = 5 donors, and n = 8 clots
per donor for a constant outlet pressure yielding an initial wall shear rate of 200 s−1. (C)
Fluorescence microscopy images for platelets (AF488 CD-61) and fibrin (AF594-conjugated
human fibrinogen) at t = 400 s.
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Figure 4.2: Healthy donor blood with Andexanet Alfa alone
Average fibrin signal for N=3 healthy donors with either 0 nM, 50 nM, or 300 nM of Xa-inhibitor
reversal agent added. No statistical significance (p>.05) was observed between 0 nM and either
of the other concentrations.

4.3.2. DOAC patient data
To assess the ability of our assay to detect the presence and activity of DOACs
in the blood of DVT patients on apixaban or rivaroxaban, an assay was designed to
utilize small volumes of reversal agent to provide a ‘control’ condition for each patient to
compare their unmodified blood with. For N=8 patients, consistent significant restoration
of the fibrin signal was observed for the addition of 300 nM of reversal agent (Figure
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4.3B,C). For 50 nM of reversal agent, an intermediate restoration of fibrin fluorescence
intensity was observed as well. As anticipated, a high concentration (5000 nM) of
matching DOAC drug (either rivaroxaban or apixaban) added to the patient blood
resulted in near abolishing of the fibrin signal. Previous studies using in vitro spiked
whole blood from healthy donors showed maximal differentiation between DOACinhibited and unmodified (control channels) channels at around 500 seconds (Figure
3.5). With the greater level of variance both in patient characteristics (age, health
history, etc) and in timing between blood collection and assay execution for these
patients, however, the time scale of clotting was found to vary more for the DVT patients
than healthy donors, even with curves that were otherwise substantially the same. For
this reason, fluorescence intensities were evaluated for each patient at the time where
the high reversal agent condition FI was 83% of its maximum value; the same
percentage the healthy donors were at for 500 seconds (Figure 3.5). This ensures that
each patient curve is being evaluated at generally the same region of the characteristic
sigmoid curve in fibrin signal (Figure 4.3A), rather than a single fixed time across all
patients. For fibrin FI evaluated this way, a statistically significant difference (p<.0001)
was observed between the unmodified blood condition and high reversal condition.
When, for each patient, the fibrin signal at the time point where the high reversal agent
condition is used to normalize the rest of the conditions, the behavior becomes more
consistent patient to patient, and this significance is maintained (Figure 4.3C).
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Figure 4.3: DVT Patient Fibrin Data
Fibrin fluorescence intensity curves for a single patient (A), where significant restoration of
signal is observed for the addition of 300 nM Andexanet Alfa (purple curve). (B) Combined data
for all N=8 patients, where only the fluorescence at the time point where where the +300 nM
Andexanet Alfa condition was at 83% of its maximal value. (C) data from B where each
patient’s data is normalized by the channel with the maximum fluorescence intensity for that
experiment (always the +300 nM Andex. condition). ****: p<.0001

Contrary to the fibrin signal, platelet fluorescent intensity was largely agnostic to
the presence of reversal agent. Regardless of the time where fluorescence intensity is
evaluated, no statistically significant difference was found between the control and the
reversed lanes [Figure 4.4A]. Limited significance was found between the patient blood
and high anticoagulant condition (p=.0045), indicating that platelets are only impacted
when thrombin is completely abolished and cannot act as a platelet antagonist. This is
also apparent in the temporal curves for the individual patients, where the +5000 nM
condition is typically visually separated from the rest of the curves after around 200
seconds. Platelet behavior is also homogenized somewhat by the normalization to
fluorescent intensity of the fully reversed channel, but not to the same extent as fibrin
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Figure 4.4: DVT Patient Platelet Data
Platelet fluorescence intensity curves for a single patient (A), where no significant restoration of
signal is observed for the addition of 300 nM Andexanet Alfa, but consistent reduction in signal is
observed for high concentrations of ex vivo inhibitor. (B) Combined data for all N=8 patients,
where only the fluorescence at 500 s is reported. (C) Data from B where each patient’s data is
normalized by the channel with the maximum fluorescence intensity for that experiment.

4.3.3. DOAC presence prediction
To evaluate the ability of our essay to differentiate blood that has reversal agent
and unmodified blood from patients, a receiver operating characteristic analysis was
performed. For normalized fibrin fluorescence intensity, complete differentiation between
patient blood and fully reversed blood was possible with an AUC of 1, and sensitivity and
specificity both equal to 100% for a cutoff threshold of normalized FI >.85 [Figure 4.5A].
Using the lower reversal agent concentration, these results were .8163, 87.5% and 75%
respectively [Figure 4.5C]. Using the raw fluorescence intensity to compare patient blood
and the 300 nM reversal agent condition, the AUC was reduced to .9063, and the
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sensitivity and specificity were 87.5% and 100% respectively, for a cutoff threshold of
FI>39.46.

Figure 4.5: ROC analysis for differentiation of reversed and unmodified blood
Receiver operating characteristic analysis for discrimination of unmodified patient blood and 300
nM reversed patient blood using normalized fibrin signal at 83% max (A) and raw fibrin signal at
83% max (B). (C) Receiver operating characteristic analysis for discrimination of unmodified
patient blood and 50 nM reversed patient blood. An AUC of 1 indicates perfect discrimination.

4.3.4. DOAC concentration prediction
In order to predict concentrations of drug present in patient blood, differences
between the fluorescence intensity for neat patient blood and patient blood treated with
high doses of reversal agent and excess doses of inhibitor were compared against dose
response data collected for whole blood from healthy, donors spiked with DOACs in vitro
(Figure 3.5). For each patient, the equivalent fluorescence intensity on the healthy donor
curve was identified according to the approach outlined in Figure 4.6, and the
corresponding concentration associated with the curve was reported (Table 3), with the
majority of patients predicted to be around 100 nM concentration, or near typical trough
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concentrations. Missing values are for patients for whom data sheets have not been
made available [103].

Figure 4.6: DOAC Concentration prediction schematic
Methodology for mapping DVT patient results to ex vivo drug addition for healthy donor results. It
is assumed here the fundamental metric of importance is the ratio between the unmodified blood
and the fully reversed (300 nM treated) blood, with the high anticoagulant condition treated
exclusively as background noise.
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Table 3: Patient information and concentration predictions
Subject

001

002

003

004

005

006

Age

68

36

51

43

37

71

007

008

009

Sex

M

F

M

F

M

M

Indication

DVT-2007

DVT-2005

Missing

DVT

DVT

DVT2015

Drug

2.5 mg A, 2x

5 mg A, 2x

2.5 mg A, 2x

5 mg A, 2x

20 mg 1 x R

2.5 mg
A, 2x

Last Dose

9.5 h

2h

4.5 h

3h

2h

11 h

Other Meds

Ascorbic acid,
glucosamine,
simvastatin,
cholecalciferol,
breo ellipta
albuterol sulfate

Tranexamic
acid,
fumerate-FA,
folic acid

Pravastatin

None

None

Statin 20
mg daly

Concentration
model @ 500 s

122 nM

104 nM

100 Nm

90 nM

40 nM

13 nM

125 Nm

117 nM

Concentration
model @ 83% max

140 nM

64 nM

63 nM

100 nM

45 nM

32 nM

122 nM

85 nM

LCMS Drug
concentration

4.4 Discussion
Although initially considered an advantage of DOACs, the lack of a required
routine testing strategy has meant that standardized methods for detection of presence
and quantification of drug concentrations has become a more and more urgent need as
adoption has increased [95,104,105]. Testing may be particularly relevant in two types of
specific scenarios: (1) acute event risk assessment and (2) individual patient dose
control. Potential acute scenarios include testing in proximity to major surgical or
invasive procedures, cases of traumatic injury and major bleeding, and prior of
fibrinolytic treatment for cases such as ischemic stroke [91,106]. Threshold
recommendations have been made by the ISTH for drug concentrations of <30 ng/mL
(~70 nM) for concentrations of apixaban, rivaroxaban and dabigtran for perioperative
situations, with 50 ng/mL (~120 nM) considered to represent moderate bleeding risk
[107]. These recommendations set the requirements for a point of care testing strategy
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to provide utility to clinicians in risk management for patients on DOACs. The
development of reversal agents for DOACs such as Andexanet Alfa for Xa inhibitors and
Idarucizumab for dabigtran have enabled clinicians to respond to situations where
bleeding is suspected, however, these reversal are prohibitively expensive at up to
$50000 per 800 mg dose, making improved information for clinicians as to their need
critical to efficient patient care [108,109].
Patient dose optimization testing may be relevant during initiation of treatment, in
cases where patients are either over or underweight, in situations where non adherence
to dosing is suspected, and in cases where possible interference from other drugs is
suspected [105,106]. Since the half-life of DOACs is significantly shorter than that of the
previously used VKA drugs, inconsistent adherence to dosage recommendations
represent a significantly greater risk of reduced protection from thromboembolism [105].
DOAC concentrations have also been demonstrated to increase dramatically in
response to antiviral agents used for COVID-19, suggesting particular disease states
and treatments may present a compelling need for DOAC monitoring [110].
Current testing methods have proved inadequate for either testing application, as
tests such as PT/INR and aPTT have been shown to be highly dependent on the
particular reagents (thromboplastins) used. ‘Normal’ readings can be produced for
concentrations of drug that are considered clinically risky for scenarios such as surgery
or bleeding events, and PT has even been reported to be insensitive to the effects of
apixaban [91,111]. In either case, no specific normalization strategy such as the INR
exists for DOACs, making results highly dependent on the particular lab they are carried
out in [106]. In more acute testing scenarios, more precise but slow or uncommon
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methods such as chromatography or chromogenic anti-Xa assays may be impracticable,
highlighting the need for fast, accurate, point of care assays [38].
The assay described in this work performs assessment of platelet and fibrin
activity under whole blood flow at physiological venous shear rates using very small
amounts of blood (<400 μL). With eight independent experimental conditions, patient
blood can be reversed on chip with extremely small amounts (~1 μg) of reversal agent,
providing an internal control for each patient and a reference point for drug action. This
concentration (300 nM andexanet alfa) was chosen such that approximately an
equimolar ratio of reversal agent to DOAC would be present based on anticipated
plasma concentrations, allowing for complete reversal of any DOAC present [103]. Using
this approach, our assay was able to detect the presence of DOAC drug in every (N=8)
patient tested, with 100% specificity and sensitivity and AUC of 1, within a test time of
less than 15 minutes, for patients on both rivaroxaban and apixaban taken together.
These results represent a significant improvement on both common laboratory methods
such as PT and aPTT where sensitivities and specificity can be in the range of 50%
depending on the thromboplastin used, and on shows an improvement on or general
parity with previously published POC diagnostic devices, albeit for a smaller sample size
[49,50,100,112].
There are some important limits to this study, including a relatively small number
of patients and data heavily weighted towards apixaban rather than rivaroxaban.
Additionally, although there is clear path forward, the assay described in this work is
inefficient for differentiating IIa and Xa inhibitors, as certain other assays have
demonstrated. If required, a second reversal agent (i.e. Idarucizumab) could be added
and by comparison between the fibrin response for each reversal agent, classification
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should be straight forward. In addition, this assay was not executed truly point of care
due to rotating clinical space in response to COVID requirements. In reality, however,
one may reasonably anticipate that the assay’s performance would only improve if
testing was performed immediately after phlebotomy for CTI anticoagulated whole blood,
as would be possible if the experimental apparatus was transferred to the hospital
setting.
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CHAPTER 5 : OTHER STUDIES

5.1 Pulsatile flow in Microfluidic Assays
5.1.1. Introduction
Rhythmic contractions of the heart muscle throughout each stage of cardiac
cycle causes blood flow to vary in magnitude and even direction at difference points in
the cycle, and to different extents depending on the blood vessel of interest. Timevarying, or pulsatile flows, have been shown to have signifcant impacts on endothelial
form and function compared with steady, unidirectional flow, with changes having been
observed in protein expression and phosporylation status of cellular adhesion molecules
[20,113,114]. Similarly, reversing flows around venous valves due to venous reflux in the
legs have been shown to be correlated with deep vein thrombosis (DVT) [115]. While
the impacts of pulsatile flow on endothelial cells have been well studied, the effects of
these flows on platelet accumulation and coagulation has not. In vitro studies of blood
flow and hemostasis modeling are typically carried out in microfluidic devices at either
constant flow rates or at a constant pressure drop, with flow only varying significantly in
the area of interest when a clot is very close to vessel occlusion [116].
It is well know that clots formed under differing flow rates and shear rates have
important differences in their composition and engagement of plasma proteins such as
von Willebrand Factor (vWF). Venous clots are typically considered “red”, or fibrin and
red blood cell rich, and arterial clots are considered “white”, or platelet rich [117]. For
arterial shear rates, vWF becomes particularly important, participating signifcantly in
platelet capture from flow at shear rates above 1000 s-1 through GP1b mediated binding
[118]. This capture then allows activation of the platelets via collagen binding of
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GPIIb/IIIa [119]. In microfluidic devices, morphological differences can be observed
between more regular clots formed under venous shear rates and more amphorphous
clots formed under arterial shear rates. Given the differences in behavior observed for
clots form under different steady state conditions, it is reasonable to assume that flow
pulsatility and thus variations in the shear rate over time may cause differences in clot
formation as well. Studies on this matter have been limited, however, and threre have
been conflicting reports on the impact of pulstaility on platelet adhesion [119–121].
Microfluidic devices have enabled a wide range of assays on hemostasis owing
to their low requirements for blood volume and flexible geometries. This work describes
an approach for carrying out similar microfluidic assays with fluid delivered in time
varying manner, in order to examine directly the impact of variations in shear rate at
physiological time scales (~1 Hz).

5.1.2. Materials and Methods
5.1.2.1

Device Design, Fabrication and Preparation

A previously designed 8-channel microfluidic device was adapted to a 4-channel
design in order to reduce the total volumetric flow of blood required to achieve high
shear rates. This new 4-channel design is otherwise identical to the previously described
device in order to maintain the flow characteristics (Figure 5.1) [26]. Devices were
prepared using poly(dimethylsiloxane) (PDMS) Sylgard 184 (Ellsworth Adhesive).
Thrombogenic surfaces were prepared by coating glass slides (75x38 mm) with
SigmaCote (Sigma Aldrich) and subsequently patterning a 250 μm strip of type I equine
fibrillar collagen (ChronoLog) using a dedicated PDMS patterning device as previously
described [61]. The collagen was subsequently coated with either tissue factor (Dade
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Innovin, Siemens), or vWF (Haematological Technlogies). A solution of 1% bovine
serum albumin (BSA) (Sigma Aldrich) in HEPES buffered saline (HBS) was used to
prime each of the devices prior to use.
5.1.2.2

Waveform generation and verification

Flow was delivered by withdrawal through the single outlet of the device with a
syringe pump (Harvard PHD ultra) connected to a 1 mL glass syringe with a fixed blunt
22G needle (Hamilton), pre-filled with de-ionized water, with all air carefully eliminated in
order to prevent compressibility in this line. In order to achieve time-varying flow, a
triangle wave was programmed into the device using the onboard firmware to define
“ramp steps” to build a triangle wave. For arterial shear rate studies, ramps were
programmed for 20 μL/min to 160 μL/min in 1 s, followed immediately by 160 μL/min to
60 μL/min in 1 s, yielding a total cycle time of 2 seconds, or frequency of 0.5 Hz and a
shear rate of 2200 s-1 +/- 75%. For venous studies, an average of 200 s-1 +/- 75% was
used. Waveforms were verified by flow rate measurement using a thermal mass flowthrough sensor and a solution of methyl cellulose in water to a viscosity of 4 cP (Fluigent
Inc).
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Figure 5.1: Pulsatile Flow Experimental Design
Experimental design where a 4-channel device is prepared using previously described methods,
and then blood is perfused using a syringe pump programmed with a time-varying flow profile
[23]. For high frequency imaging, a 90 fps camera is utilized.

5.1.2.3

Blood Collection

Blood was obtained from consenting healthy adult donors via venipuncture into
corn trypsin inhibitor (CTI, Haematologic Technologies) or H-D-Phe-Pro-Argchloromethylketone (PPACK, Bachem) to final concentrations of either 40 μg mL-1 or 100
μM to prevent contact (XIIa) activation or thrombin generation respectively. All
procedures were performed in accordance with protocols outline and approved by the
University of Pennsylvania’s Institutional Review Board.
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5.1.2.4

Platelet and Fibrin Imaging

Platelets were labeled with PE-mouse anti-human CD61 (BD) and fibrinogen was
quantified using alexafluor-647 conjugated human fibrinogen (Life Technologies).
Devices were imaged on an inverted epifluorescence microscope (Olympus IX81) and
images captured with either an ORCA-ER CCD camera (Hamamatsu) or a high
framerate firewire-800 camera (Unibrain). Simultaneously experiments were run on the
same equipment; one for a steady shear rate, and one for a pulsatile flow, using two
different syringe pumps.

5.1.3. Results
In order to verify the function of the triangle waveform in delivering pulsatile flow
at high flow rates, a thermal mass based flowrate sensor was used with a methyl
cellulose solution in water to model blood viscosity. For a 0.5 Hz wave at 2200 s-1 +/75%, flowrates confirmed precisely to expectation, reaching a peak of 160 μL/min and
dropping all the way to 20 μL/min within in 1 second, repeatably as shown in Figure 5.2.
Sine waves were also demonstrated as feasable, but were not used in experiment due
to requiring external communication with the PHD ultra pump to continuously vary the
flow rate set point. It is important to note that without the use of a fused needle tip
syringe, less consistent behavior was observed, likely due to the increased dead volume
added by connecting a luer lock plastic hub needle to a luer syringe. Flow rate
measurements for an average shear rate of 200 s-1 showed similar fidelity. Flow rate
fidelity at arterial shear rates was further confirmed by high frame rate acquistion (90
fps). Inspection of the platelet fluorescence intensity for the triangle waveform showed
changes in brightness of the same frequency as the waveform (0.5 Hz) (Figure 5.3). This

75

was confirmed by calculating the fast fourier transform of the platelet signal, yielding a
peak in the power spectrum at 0.5 Hz (Figure 5.3B). In experiments where TF was
present and fibrin was monitored, a corresponding response in the fibrin fluorescence
was not observed, suggesting platelets may adhere and be removed within a single
waveform cycle, but fibrin is protected from this process, possibly due to forming in close
proximity to the glass slide at the tissue factor surface.

Figure 5.2: Pulsatile Waveform Verification
Flow rates detecting using the Fluigent FRP thermal mass flow rate detection system for 4 cP
buffer containing methyl cellulose, for a sine wave input (A) or triangle wave input (B). Flow rates
correspond to 2200 s-1 +/- 75% in each lane of a 4-channel microfluidic device.
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Figure 5.3: Frequency analysis of platelet and fibrin for pulsatile flow
Platelet (A) and fibrin (B) fluorescence intensity for a single channel perfused with a triangle
waveform, with images captured at 90 frames per second. Due to the frame rate, both channels
cannot be image at once, so there is no fibrin data for the first 350 seconds. Panels (B) and (D)
are the same data with the axes truncated to better visualize the time varying response. Plates
(B) respond in time with the 0.5 Hz waveform used, as verified by fourier analysis (inset). Fibrin
(D) does not shome the same time varying response.

At an average shear rate of 200 s-1 flow pulsatility had no observable effect on the
platelet accumulation in PPACK whole blood when compared with a steady flow rate
(Figure 5.4C). In contrast, signifcant differences were observed for PPACK blood
perfused with a triangle wave, with greatly enhanced platelet accumulation occuring for
the unsteady flow (Figure 5.4A). This may be due to the fact that during the low flow
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rate regions of the pulse cycle, platelets are able to adhere preferentially, and remain
adherent through the higher shear portion of the cycle. Minimal platelet adhesion was
observed for the constant flow case at 2200 s-1, suggesting vWF from circulation did not
adsorb to the collagen and faciliate adhesion to a significant extent in these experiments.
When the same experiment was run for CTI blood with a collagen and tissue surface,
differences between the two flow profiles largely disappeared, suggesting fibrin may help
stabilize platelets against removal at high shear rates, or that platelets activated by
thrombin may have strong adhesion forces (Figure 5.4B).

2200 s-1
N=5
PPACK

200 s-1

2200 s-1
N=4
CTI(+TF)

N=4
PPACK

Figure 5.4: Platelet fluorescent intensity in constant versus pulsatile flow
Average platelet signal for N=5 donors, for PPACK whole blood perfused over collagen with
either a triangle wave at 2200 s-1 +/- 75% or steady flow at 2200 s-1 (A), CTI whole blood
perfused over collagen with tissue factor, with either a triangle wave at 2200 s -1 +/- 75% or steady
flow at 2200 s-1 (B). (C) Average platelet signal for N=5 donors, for PPACK whole blood perfused
over collagen with either a triangle wave at 200 s-1 +/- 75%or steady flow at 200s-1.

When vWF was coated to the the collagen thrombogenic surface instead of TF,
the comparative enhancement of platelet accumulation was reduced for pulsatile flow
versus constant, in relation to the results with no vWF present. This is likely attributed to

78

vWF faciliating adhesion of platelets at high shear rates, reducing the relative impact of
the lower shear excursions of the triangle waveform. Some enhancement is still
observed, however, suggesting vWF alone does not render the platelets completely
agnostic to flow profiles. It should be noted that there may have been a vast excess of
vWF present on the collagen compared to true physiology, as the stock was coated to
collagen at the full concentration from the supplier, and no quantification was performed
for the amount deposited.

Figure 5.5: Platelet fluorescence intensity with CTI blood and a vWF/collagen surface
PPACK whole blood perfused over collagen pre-coated with vWF, with either a triangle wave at
2200 s-1 +/- 75% or constant flow at 2200 s-1.
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5.1.4. Discussion
Platelet adhesion onto collagen alone was not impacted by pulsatility in flow at
venous shear rates at an average of 200 s-1. This is not unexpected, as at these shear
rates platelets can likely adequately adhere to the collagen at all points in the flow rate
cycle realtively equally, meaning the total flux of platelets is the critical determining factor
for depostion. Since the average flow rate is the same for either steady or pulsatile flow,
therefore, similar accumulation was observed. Conversely, at arterial shear rates, a
substantial difference was observed for platelets adhering to collagen alone for pulsatile
versus constant flow. It is well known that as shear rate increases above ~1000 s-1
platelet adhesion without vWF is significantly impaired [122–124] . For patelet
aggregation to occur at high shear rates, it is likely platelets first bind transiently to vWF
via the GPIb receptor, although this interaction is weak and short-lived. During the
platelet interaction with the vWF, where a brief period of rolling adjacent to the surface
may occur, however, stronger bonds can form via the GpIIb/IIIa integrin and platelets
can become firmly adherent [124]. It is possible that in this study, in the absence of
significant amounts of vWF, the low shear rate portions of the pulse cycle function in a
similar way. Platelets are allowed to associate more easily with the collagen surface at
the troughs of the wave form, during which significant platelet activation and bonding via
GpIIb/IIIa can occur which then protect the newly aggregated platelets from shearing off
at the peaks of the waveform. This idea is supported by the appearance of Figure 5.3B,
where a steep increase in platelet fluorescence intensity is observed with the same
frequency as the waveform.
Enhancement of platelet accumulation during pulsatile flow was not observed
under all cases at arterial shear rates. With a collagen-TF surface and CTI
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anticoagulated blood, differences between steady and pulsatile flow were essentially
eliminated. Previous studies have suggested that cleaving of the protease activated
receptor-4 (PAR4) by peptides increases the aggregation strength of platelets and their
resistance to shear stress [125]. It is possible, therefore, that the presence of thrombin in
the collagen-TF experiments results in significant engagement of PAR4, stabilizing the
platelet mass against shear stress based erosion. In the case of vWF coated onto
collagen, reduced differentiation was observed between pulstile and steady flows at
arterial shear rates. This is consistent with the idea that vWF-mediate periods of
prolonged residence time near at the thrombogenic surface facilitate platelet adhesion.
This process enables much more significant adhesion for steady flow at 2200 s-1 than
collagen alone, as evidenced by the relative platelet accumulation in Figure 5.4A
compared with Figure 5.5. This process may be slightly more efficient at shear rates
<1500 s-1, allowing for a small increase in platelet accumulation to remain for pulsatile
flow even with vWF present.

5.2 Measuring the intraclot diffusion using FRAP
5.2.1. Introduction
Consideration of mass transport through growing thrombi is of critical importance
to full understanding of thrombosis. Upon initial endothelial damage upon injury at a
vessel wall, coagulation factors from circulation have relatively open access tissue factor
allowing coagulating to procede. As a platelet and fibrin thrombus accumulates on top of
the initial injury site, however, coagulation factors such as factor X would potentially
need to diffuse through an increasingly thick and dense barrier to reach this tissue factor
rich site, however [126]. Similarly, diffusion of thrombin formed adjacent to the the tissue
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factor bearing surface must diffuse out through the clot to become available to cleave
fibrinogen and platelet PAR receptors [127,128]. In either case, developing and accurate
model of intra thrombus transport requires some degree of knowledge of the rate of
diffusion through the clot. Previous measurements have suggested extremely low rates
of diffusion for factor Xa, implying up to a 4 hour requirement for diffusion through 1 mm
of platelet clot. For diffusion this limited, the fact that it is well known that clots can fully
occlude vessels in less than 10 minutes requires a complete change in understanding of
the fundamentals of thrombosis, for example requiring a secondary procoagulant source
at the outer surface of a growing thrombus such as bloodborne tissue factor or plateletderived factor XI for occlusive thrombi to form [126]. In this way, accurate information on
transport parameters for relevant coagulation factors is critical to complete
understanding of hemostasis and thrombosis.
Fluorescence recovery after photobleaching (FRAP) is a technique often used to
measure the kinetics of diffusion on membranes and cell surfaces [129]. Briefly, a region
of interest with fluroescent analyte present is exposed to high intensity light which
bleaches all of the exposed area leaving a ‘hole’. Subsequently, lower intensity light is
used to observe a larger region around the bleaching region in order to observe the
diffusion of unbleached molecules from the surrounding area into the ‘hole’ and diffusion
of bleached molecules out of the ‘hole’, and thus a recovery in the brightness of the
exposed area. Analysis of the rate of recovery after the bleaching process enables
inference of the diffusion rate of the molecules of interest in the particular environment of
the experiment. This method is typically applied at very small length scales, but has
been demonstrated for inhomogeneous tissues [130]. In this way, applicatin of FRAP
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techniques to measure to the diffusion of analytes of interest through a thrombus may
provide unique insight into transport parameters of thrombosis.

5.2.2. Materials and Methods
Whole blood collected from a healthy donor and anti-coagulated with 100 µM
PPACK was dosed with 1 mg/mL FITC-conjugated bovine serum albumin and perfused
over a 250 μm strip of Type I fibrillar collagen (equine) patterned on a glass, using an 8channel PDMS microfluidic device, with the flow rate maintained at a constant 8 μL/min
by a syringe pump (Harvard PHD ULTRA). Upon channel occlusion, the device was
decoupled from the syringe pump and moved to a Zeiss LSM 710 Laser-scanning
confocal microscope for FRAP data acquisition. The clot was continuously illuminated in
a 70 μm diameter circular region for 24 seconds at 100% laser power using a 488 nm
wavelength in order to bleach the FITC-albumin located in the interstitial volume
between platelets. Post-bleach frames were captured using a 20x objective at a rate of 1
frame every 3 seconds for a total of 140 seconds in order to capture the rate of
brightness recovery due to the diffusion of unbleached albumin molecules. A modified
bessel function fit of the recovery data was performed to determine a diffusion coefficient
[131].

5.2.3. Results and Discussion
Photobleaching of the FITC-albumin was incomplete even for a 24 second
exposure. It is not entirely clear why this was the case, as FITC is a commonly used
molecular probe for FRAP experiments, and should bleach readily [132]. Since an
“immobile fraction” of albumin was likely adsorbed to the platelet surface, incomplete
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recovery of fluorescence was also observed in the resulting time-lapse profiles – the
absorbed albumin was not displaced with new albumin during the recovery period Figure
5.6B. To account for this, the fluorescence intensity of the bleach region was normalized
assuming the final time point had recovered to 96% of the asymptotic value for the
mobile fraction. The data was compared against a modified bessel functin fit for diffusion
limited recovery, suggesting an effective diffusion coefficient for albumin in a platelet clot
generated under flow of 1.1x10-7 cm2/s – the typically reported value for albumin diffusion
constant in water is ~6 x 10-7 cm/s [133]. It should be noted that the fit used to model the
recovery data assumes 1) instantaneous bleaching, 2) complete bleaching in form a step
function in brightness 3) no relevant diffusion in the z-axis 4) that the experimental media
is isotropic. None of these assumptions holds completely, and thus there is likely some
possibly significant error in the calculated diffusion coefficent, however, this data serves
as a proof of concept.

Figure 5.6: FRAP Data for Diffusion of FITC-albumin
(A) Fluorescence image of a platelet clot formed in a PDMS microfluidic device, with FITCconjugated albumin mixed with the blood prior to perfusion. (B) Brightness response to
bleaching with a laser-scanning confocal microscope at maximum power for 24 seconds.
Incomplete bleaching is observed and a substantial immobile fraction is present. (C) A sample
of the curve from (B), post bleach, with the recovery profile fit to a modified bessel function
described by Soumpassis (inset).
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CHAPTER 6 : FUTURE WORK
6.1 Clot cytometry
Optical flow cytometers have been utilized for more than half a century to provide
large-scale automated diagnostic information on cell populations, such as for diagnostic
detection of markers of blood cancers [134] . A laser illuminates a stream of cells
dispersed in solution, tapered down to a single cell at a time, and the scattering or
absorption and emission of the incident light from the laser is thereafter detected by
optical sensors. In addition to simple fluorescence, detectors can differentiate forward
scattering of light in order to infer cell size and side-scatterd light to indicate cellular
granularity and therefore help determine cell type [135]. Their ability to process huge
numbers of cells (over 70000 cells per second in some cases), in a multiplexed way has
made optical flow cytometers an invaluable tool.
Clots formed in vitro have been an area of increased interesting over the last two
decades owing to the devlopment of microfluidic flow device technology. Microfluidics
have allowed the study of numerous analytes, from the obvious such as platelets and
fibrin, to others of more recent interest such as neutrophil extracellular traps (NETs)
[136]. In reality, a plurarlity of potential analytes of interest exist that may localize in
growing thrombi. Several analytes are directly related to hemostasis such as vWF, pselectin, PAC1, CD61, CD63, CD151, phosphatidylserine (PS), factor XIIIa, and fibrin
have been studied previously. Other analytes of interest, however, may also localize in
thrombi to signifcant degrees, including markers of inflammation and cancer due to
cross-talk between inflammatory and coagulation processes. HMGB1 has been
implicated in deep vein thrombosis (DVT), elevated levels of C-reactive protein and
Pentraxin 3 have been associated with increase risk of heart attack [137–139].
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Similarly, complement proteins C5a and C3a have been shown to interact with thrombus
formation via recruitment of neutrophils during myocardial infarction [140]. The serine
protease Cathepsin G has also been connected with modulation of platelet clot formation
through interactions with neutrophils [141]. Increased levels of plasminogen activator
inhibitor-1 (PAI-1) and Carboxypeptidase CPB2 have also been associated with vascular
thromboembolism [142,143]. Serum amyloid A has been found to to bind to fibrinogen
and promote amyloid formation [144]. Thrombospondin-1 can interact with vWF to
modulate arterial thrombosis and impact platelet recruitment [145].
Using a multiplexed microfluidic device and a multicolor microscope to study
clots formed under whole blood flow, the kind of diagnostic approaches which have been
applied for flow cytometry could be taken advantage of to perform what is essentially
“clot cytometry”. With a 3-color microscope and 8 channel microfluidic device, 24
analytes could be interrogated simulatenously. Growing thrombi may provide a locus in
which certain more low concentratin analytes may accumulate. For data collected in the
chips described in Chapter 3, with imaging by an Olympus IX81 microscope, imaging of
several analytes has already been demonstrated (Figure 6.1). Optimization of conditions
to obtain quantifiable signals for the other analytes of interest remains to be done,
particularly for the inflammation markers which may be at much lower concentrations.
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Figure 6.1: Example Data for Clot Cytometry
Proof of concept images for clots formed simultaneously in an 8-channel microfluidic device with
staining for 8 different analytes (pseudocolor). Contrast for each image was adjusted
independently, as signal for TSP1, vWF and thrombin were notably weaker than the others.
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CHAPTER 7 : APPENDIX I (SUPPLEMENTAL FIGURES)

Supplemental Figure 1. Components for final chip assembly, including the injection
molded chip with channels (A), the adhesive used to form “bottom” surface (B), a check
valve used for priming the device which is the closed (C), an Ink roller which is used to
laminate the adhesive to the chip (D), and the final assembled chip filled with blue food
coloring for visualization.

88

Supplemental Figure 2. Wall shear rate at focal region for channels 1-4 for an inlet
pressure of 16000 Pa (channels 5-8 omitted as device is symmetric).

Supplemental Figure 3. (A) 4 individual fluorescence peaks from FITC calibration kit,
mixed in equal proportion by pipette. (B) Bead solutions from peaks 1-4 added
symmetrically to device such that channels mirrored about centerline of the chip have
the same bead peak, perfused through device, and effluent measured. Bead counts from
each peak reported as a fraction of count from manually pipetted mixture.
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Supplemental Figure 4. (A) 8 by 1 channel orientation, re-designed from the 4 by 2
described in chapter 3. (B) Results from 3D laminar flow steady state COMSOL
simulations, indicating equal shear rates in each channel.
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Supplemental Figure 5. Assay design for DVT patients. Unmodified patient blood
condition was split between ends of the device to help prevent too large an asymmetry in
forming in the resistance caused by channel occlusion across the device as the
experiment proceeded.
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CHAPTER 8 : APPENDIX II (PATENT APPLICATION)
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